Aromatic amide derivative, preparation method therefor, and use thereof in medicine
By designing aromatic amide derivatives as KIF18A inhibitors, the problem of lacking effective inhibitors in existing technologies has been solved, enabling effective treatment of various cancers. In particular, by influencing microtubule dynamic instability to inhibit KIF18A activity and promote cancer cell apoptosis.
Patent Information
- Application Number
- PCT/CN2024/091661
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2024-05-08
- Publication Date
- 2024-11-21
AI Technical Summary
There is a lack of effective inhibitors targeting KIF18A in the current technology. KIF18A is highly expressed in a variety of cancers, affecting the occurrence and development of tumors, and its mechanism of action is not yet fully understood.
An aromatic amide derivative has been developed and, through specific structural design, can be used as an inhibitor of KIF18A to prepare pharmaceutical compositions for the treatment of KIF18A-mediated diseases such as hepatocellular carcinoma, glioblastoma, and colon cancer.
It effectively inhibits the activity of KIF18A, slows down cancer development, and promotes cell apoptosis by affecting microtubule dynamic instability, providing a new therapeutic approach.
Smart Images

Figure CN2024091661_21112024_PF_FP_ABST
Abstract
Description
Aromatic amide derivatives, preparation methods thereof and their use in medicine Technical Field
[0001] The present invention relates to an aromatic amide derivative, a preparation method thereof, a pharmaceutical composition containing the derivative, and use of the derivative as a therapeutic agent, in particular as a KIF18A inhibitor. Background Art
[0002] Kinesin molecules are motor proteins that use microtubules as tracks and play an important role in organelle migration, tissue and organ development, signal transduction, mitosis, meiosis, and other processes. Various microtubule-associated proteins (MAPs) in the kinesin-8 family regulate microtubule dynamic instability by affecting microtubule polymerization and depolymerization. KIF18A, a member of the kinesin-8 family, can move toward the positive pole using microtubules as tracks and prefers to bind to longer microtubules. Its activity is length-dependent and affects the length of the spindle, ensuring the timely and smooth alignment of sister chromosomes. Its functions are very similar and conserved across species.
[0003] KIF18A is a molecular motor protein that moves along microtubules toward the plus-end of microtubules. It regulates chromosome midplate assembly by influencing the dynamic instability of microtubule ends, thus functioning during mitosis. During anaphase, the protein is ubiquitinated and degraded, ensuring precise chromosome segregation during mitosis and enabling the successful completion of mitosis and cytokinesis. During early mitosis, KIF18A localization to the plus-end of microtubules near the kinetochore is essential for its function. This localization depends not only on the motor activity of its N-terminus but also on the microtubule-binding tail domain. KIF18A is also subject to reversible phosphorylation / dephosphorylation, but how these post-translational modifications regulate KIF18A function remains understudied. The estrogen receptor ERɑ binds to KIF18A and promotes its transcription, but whether KIF18A is regulated by other transcription factors remains unclear. Therefore, further research is needed into the mechanisms regulating KIF18A's gene transcription. During meiosis, cells lacking KIF18A will be unable to complete meiosis, which will lead to sperm formation disorders and testicular dysplasia in male animals.
[0004] Studies have found that KIF18A protein is highly expressed in a variety of cancers, including but not limited to hepatocellular carcinoma, glioblastoma, colon cancer, breast cancer, lung cancer, bile duct cancer, pancreatic cancer, prostate cancer, bladder cancer, head cancer, neck cancer, cervical cancer, ovarian cancer, synovial sarcoma, and rhabdomyosarcoma. This suggests that KIF18A is closely associated with the occurrence and progression of tumors and could serve as a target for molecular diagnosis and treatment of various tumors. KIF18A expression is associated with the progression of clinical colorectal cancer. Studies have shown that KIF18A can induce Akt phosphorylation, and knocking out KIF18A in mice significantly promotes cell apoptosis. It is speculated that KIF18A promotes the occurrence and progression of colorectal cancer by activating the PI3K-Akt signaling pathway. KIF18A is also highly expressed in human breast cancer cells, and its overexpression is associated with breast tumor grade, migration, and prognosis. Studies in breast cancer cells have revealed that overexpression of KIF18A leads to the formation of multinucleated cells, while low expression significantly reduces cell proliferation both in vitro and in vivo. This is attributed to KIF18A stabilizing microtubules at their ends and inactivating the PI3K-Akt signaling pathway, leading to apoptosis. Furthermore, KIF18A is upregulated at both the transcriptional and translational levels in lung adenocarcinoma, and abnormal KIF18A expression correlates with clinical and pathological malignancy. KIF18 gene mutations have been observed in lung adenocarcinoma, and its expression is also regulated by DNA copy number. KIF18A knockout inhibits lung adenocarcinoma cell proliferation in vitro and in vivo, inducing apoptosis and G2 / M arrest. Genes that are overexpressed alongside KIF18A are concentrated in cell cycle signaling pathways, thus further investigation of the mechanisms of action of KIF18A in tumors is of great clinical significance.
[0005] No new KIF18A inhibitors have been marketed, and currently only Amgen's AMG-650 has entered Phase I clinical trials. As a cutting-edge research area, KIF18A remains a promising target for further investigation, necessitating continued study of its mechanism of action and the development of new inhibitors.
[0006] Summary of the Invention
[0007] In order to solve the above technical problems, the present invention provides an aromatic amide derivative represented by general formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts:
[0008] in:
[0009] G is selected from 5-10 membered bridged heterocyclic group, 5-10 membered fused heterocyclic group or 7-14 membered bispiro heterocyclic group, wherein the bridged heterocyclic group or fused heterocyclic group is optionally further substituted by one or more R A replaced by;
[0010] R Ais selected from halogen, hydroxy, cyano, alkyl, cycloalkyl or alkoxy, wherein the alkyl, cycloalkyl or alkoxy is optionally further substituted with one or more substituents selected from halogen, hydroxy, cyano, alkyl or alkoxy;
[0011] Or, two R A The same carbon atom to which it is connected forms a -C(O), -C=CR g R h , 3-6 membered cycloalkyl or 3-6 membered heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally further substituted by one or more substituents selected from halogen, hydroxy, cyano, alkyl, haloalkyl, alkoxy or =O; R g 、R h are each independently selected from a hydrogen atom, a deuterium atom, a halogen or an alkyl group;
[0012] X1 and X2 are each independently selected from CR a or N atoms;
[0013] Y1, Y2, and Y3 are each independently selected from CR b or N atoms, and at most two atoms among Y1, Y2, and Y3 are N atoms at the same time;
[0014] R a 、R b Each is independently selected from hydrogen, halogen, hydroxy, cyano, alkyl, alkoxy, -C(O)NH2, -N(CH3)2 or acetyl; wherein the alkyl or alkoxy is optionally further substituted with one or more substituents selected from halogen, hydroxy, cyano, alkyl, -N(CH3)2 or alkoxy;
[0015] L1 is selected from a bond, -C 1-6 Alkylene-, -C 0-4 Alkylene-NR c S(=O)(=NH)-C 0-4 Alkylene-, -C 0-4 Alkylene-SC 0-4 Alkylene-, -C 0-4 Alkylene-S(=O)-C 0-4 Alkylene-, -C 0-4 Alkylene-SO2-C 0-4 Alkylene-, -C 0-4 Alkylene-S(=O)(=NH)-C 0-4 Alkylene-, -C 0-4 Alkylene-NR c SO2-C 0-4 Alkylene-, -C 0-4 Alkylene-SO2NR c -C 0-4Alkylene-, -C 0-4 Alkylene-OC 0-4 Alkylene-, -C 0-4 Alkylene-NR c -C 0-4 Alkylene-, -C 0-4 Alkylene-NR c SO2NR c -C 0-4 Alkylene-, -C 0-4 Alkylene-NR c C(O)NR c -C 0-4 Alkylene-, -C 0-4 Alkylene-C(O)NR c -C 0-4 Alkylene-, -C 0-4 Alkylene-NR c C(O)-C 0-4 Alkylene-, -C 0-4 Alkylene-PC 0-4 Alkylene-, -C 0-4 Alkylene-P(=O)2-C 0-4 Alkylene, -C 0-4 Alkylene-C(=O)-C 0-4 Alkylene- or -C 0-4 Alkylene-C(=N(OH))-C 0-4 Alkylene-, wherein the -C 1-6 Alkylene- or -C 0-4 Alkylene - optionally further substituted with one or more substituents selected from halogen, hydroxy, cyano, cycloalkyl or alkoxy;
[0016] R c are each independently selected from a hydrogen atom, an alkyl group or a cycloalkyl group;
[0017] R 1 is selected from hydrogen, cyano, halogen, alkyl, hydroxy, cycloalkyl, heterocyclic, aryl or heteroaryl; wherein the alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR9 C(O)R 10 substituted by a substituent;
[0018] L2 is selected from
[0019] R B are independently selected from hydrogen, alkyl or cycloalkyl, wherein the alkyl or cycloalkyl is optionally further substituted by one or more substituents selected from halogen, hydroxy, cyano or alkoxy. B is a hydrogen atom;
[0020] R 2 、R 3 Each is independently selected from a hydrogen atom, a halogen, a hydroxyl, a cyano group, an alkyl group, a cycloalkyl group or an alkoxy group; wherein the alkyl group, the cycloalkyl group or the alkoxy group is optionally further substituted with one or more substituents selected from a halogen, a hydroxyl, a cyano group, an alkyl group or an alkoxy group;
[0021] Or, R 2 and R 3 Together with the carbon atom to which it is attached, it forms a 5-7 membered cycloalkyl, 5-7 membered heteroaryl or 5-7 membered heterocyclic group, wherein the cycloalkyl, heteroaryl or heterocyclic group is optionally further substituted with one or more substituents selected from halogen, hydroxy, cyano, alkyl, haloalkyl, cycloalkyl, alkoxy, haloalkoxy or =O;
[0022] R 4 Selected from cyano, halogen, alkyl, hydroxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR 5 、-C(O)R 5 、-C(O)OR 5 、-NHC(O)R 5 、-NHC(O)OR 5 、-NR 6 R 7 、-C(O)NR 6 R 7 、-CH2NHC(O)OR 5 、-CH2NR 6 R 7 or -S(O) r R 5 wherein the alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent;
[0023] Or, when X2 is CR a When R 3 or R 4 and R a The carbon atom to which it is connected forms a 5-7 membered cycloalkyl, 5-7 membered heteroaryl or 5-7 membered heterocyclic group, wherein the cycloalkyl, heteroaryl or heterocyclic group is optionally further substituted with one or more halogen, hydroxyl, cyano, alkyl, cycloalkyl, alkoxy, haloalkoxy, -OR 11 or substituted by a substituent of =O;
[0024] Or, when X1 is CR a When R 4 and R a The carbon atom to which it is connected forms a 5-7 membered cycloalkyl, 5-7 membered heteroaryl or 5-7 membered heterocyclic group, wherein the cycloalkyl, heteroaryl or heterocyclic group is optionally further substituted with one or more halogen, hydroxyl, cyano, alkyl, cycloalkyl, alkoxy, haloalkoxy, -OR 11 or substituted by a substituent of =O;
[0025] R 11 Each is independently selected from cycloalkyl or heterocyclic group; wherein the cycloalkyl or heterocyclic group is optionally further substituted by one or more substituents selected from hydroxy, halogen, cyano, alkyl, alkoxy, haloalkyl;
[0026] R 5 Each is independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted by one or more hydroxyl groups, halogen groups, nitro groups, cyano groups, alkyl groups, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyl groups, heterocyclic groups, aryl groups, heteroaryl groups, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent;
[0027] R 6 and R 7 Each is independently selected from hydrogen, hydroxy, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent;
[0028] Or, R 6 and R 7 Together with the atoms to which they are attached, they form a 4- to 8-membered heterocyclic group, wherein the 4- to 8-membered heterocyclic group contains one or more N, O, or S(O)r, and the 4- to 8-membered heterocyclic group is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic group, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent;
[0029] R 8 、R 9 and R 10 Each is independently selected from a hydrogen atom, an alkyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted with one or more substituents selected from a hydroxyl group, a halogen group, a nitro group, an amino group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, a carboxyl group or a carboxylate group;
[0030] r is independently 0, 1 or 2.
[0031] A preferred embodiment of the present invention is a compound of formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts, which is a compound of formula (II-1) or (II-2) or its stereoisomers, tautomers or pharmaceutically acceptable salts:
[0032] Among them, G, X1, X2, Y1, Y2, Y3, R 1 ~R 4 and L1 are as defined in the general formula (I).
[0033] A preferred embodiment of the present invention is a compound of formula (I), (II-1) or (II-2) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein G is selected from the following groups:
[0034] Among them, R A are each independently selected from halogen, hydroxy, cyano, methyl, trifluoromethyl, cyclopropyl or methoxy;
[0035] Or, two R A to form a cyclopropyl or cyclobutyl group with the same carbon atom to which it is attached;
[0036] n is each independently selected from 0, 1, 2 or 3.
[0037] A preferred embodiment of the present invention is a compound of formula (I), (II-1) or (II-2) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein G is selected from the following groups:
[0038] A preferred embodiment of the present invention is a compound of formula (I), (II-1) or (II-2) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein:
[0039] L1 is selected from a bond, -NR c -C 0-4 Alkylene-, -NR c SO2-C 0-4 Alkylene-, -SO2NR c -C 0-4 Alkylene-, -NR c SO2NR c -, -S(=O)(=NH)-, -NR c S(=O)(=NH)-, -C 1-4 Alkylene-, -S(=O)-, -O-, -C(=O)-, -C(=O)NR c -C 0-4 Alkylene-, -C0-4 Alkylene-SO2-C 0-4 Alkylene-, -C=N(OH)- or -NR c -C(=O)-, wherein the -C 0-4 Alkylene- or -C 1-4 Alkylene - optionally further substituted with one or more substituents selected from halogen, hydroxy, cyano, cyclopropyl or methoxy;
[0040] R c are each independently selected from a hydrogen atom or a methyl group.
[0041] A preferred embodiment of the present invention is a compound of formula (I), (II-1) or (II-2) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein:
[0042] L1 is selected from a bond, -NHCH2CH2-, -NHSO2-, -NHSO2CH2-, -NHSO2CH2CH2-, -SO2NH-, -SO2NHCH2CH2-, -NHSO2NH-, -NHSO2N(CH3)-, -SO2-, -CH2SO2-, -S(=O)(=NH)-, -NHC(CH3)2CH2-, -C(O)NHCH2CH2-, -C(O)NHC(CH3)2CH2-, -C(O)N(CH3)CH2CH2-, -NHSO2CH(CH3)CH2-, -SO2NHC(CH3)2CH2-, -C(O)NH- or -CH2SO2CH2CH2-.
[0043] A preferred embodiment of the present invention is a compound of formula (I), (II-1) or (II-2) or its stereoisomers, tautomers or pharmaceutically acceptable salts, wherein R 1 is selected from hydrogen atom, hydroxyl, alkyl, heterocyclic, cycloalkyl or heteroaryl, wherein the alkyl, heterocyclic, cycloalkyl or heteroaryl is optionally further substituted by one or more substituents selected from hydroxyl or alkyl.
[0044] A preferred embodiment of the present invention is a compound of formula (I), (II-1) or (II-2) or its stereoisomers, tautomers or pharmaceutically acceptable salts, wherein for
[0045] A preferred embodiment of the present invention is a compound of formula (I), (II-1) or (II-2) or its stereoisomers, tautomers or pharmaceutically acceptable salts, wherein X1 and X2 are each independently selected from CH or N.
[0046] A preferred embodiment of the present invention is a compound of formula (I), (II-1) or (II-2) or its stereoisomers, tautomers or pharmaceutically acceptable salts, wherein R 2 、R 3 Each is independently selected from a hydrogen atom or an alkyl group; preferably, the alkyl group is a methyl group.
[0047] A preferred embodiment of the present invention is a compound of formula (I), (II-1) or (II-2) or its stereoisomers, tautomers or pharmaceutically acceptable salts, wherein R 4 Each is independently selected from a 3- to 10-membered heterocyclyl or a 3- to 10-membered cycloalkyl, wherein the heterocyclyl or cycloalkyl is optionally further substituted by one or more alkyl or halogen.
[0048] A preferred embodiment of the present invention is a compound of formula (I), (II-1) or (II-2) or its stereoisomers, tautomers or pharmaceutically acceptable salts, wherein R 4 for
[0049] In a preferred embodiment of the present invention, the compound described by the general formula is selected from:
[0050] or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.
[0051] Note: If there is a discrepancy between a drawn structure and the name given for that structure, the drawn structure will be given greater weight.
[0052] Furthermore, the present invention provides a pharmaceutical composition comprising an effective dose of a compound of formula (I), (II-1) or (II-2) or its stereoisomers, tautomers or pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier, excipient or a combination thereof.
[0053] The present invention provides a use of a compound of formula (I), (II-1) or (II-2) or its stereoisomers, tautomers or pharmaceutically acceptable salts, or a pharmaceutical composition thereof in the preparation of a KIF18A inhibitor.
[0054] The present invention also provides a use of a compound of formula (I), (II-1) or (II-2) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in the preparation of a medicament for treating a disease mediated by KIF18A, wherein the disease mediated by KIF18A is preferably cancer; wherein the disease mediated by KIF18A is selected from hepatocellular carcinoma, glioblastoma, colon cancer, breast cancer, lung cancer, bile duct cancer, pancreatic cancer, prostate cancer, bladder cancer, head cancer, neck cancer, cervical cancer, ovarian cancer, synovial sarcoma, rhabdomyosarcoma, colorectal cancer or lung adenocarcinoma.
[0055] The present invention further provides a use of a compound of formula (I), (II-1) or (II-2) or its stereoisomers, tautomers or pharmaceutically acceptable salts, or a pharmaceutical composition thereof in the preparation of a drug for treating cancer.
[0056] The present invention provides a compound of general formula (I), (II-1) or (II-2) or its stereoisomers, tautomers or pharmaceutically acceptable salts, or a pharmaceutical composition thereof, for use in preparing a medicament for treating hepatocellular carcinoma, glioblastoma, colon cancer, breast cancer, lung cancer, bile duct cancer, pancreatic cancer, prostate cancer, bladder cancer, head cancer, neck cancer, cervical cancer, ovarian cancer, synovial sarcoma, rhabdomyosarcoma, colorectal cancer or lung adenocarcinoma.
[0057] Detailed Description of the Invention
[0058] Unless otherwise stated, some of the terms used in the specification and claims of the present invention are defined as follows: "Alkyl" when taken as a group or a part of a group refers to a C1-C 20 A straight chain or branched aliphatic hydrocarbon group. Preferably C1-C 10 Alkyl, more preferably C1-C6 alkyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc. Alkyl can be substituted or unsubstituted.
[0059] “C α-β"Alkylene" refers to an aliphatic hydrocarbon group containing a minimum of α and a maximum of β carbon atoms in a branched or linear relationship, having two residues derived from the same carbon atom or two different carbon atoms of a parent alkane by removing two hydrogen atoms, wherein α and β represent integers, the designation of C0 alkylene represents a direct bond, and C 1-6 Examples of alkylene include, but are not limited to, methylene, 1,1-ethylene, 1,2-ethylene, 1,1-propylene, 1,2-propylene, 1,3-propylene, 1,4-butylene, and the like. α-β The alkylene group may be substituted or unsubstituted.
[0060] "Cycloalkyl" refers to a non-aromatic cyclic alkyl group in which one or more of the ring atoms is a carbon atom, including monocyclic, polycyclic, fused, bridged, and spirocyclic rings, preferably having a 5- to 7-membered monocyclic ring or a 7- to 10-membered bicyclic or tricyclic ring. Examples of "cycloalkyl" include, but are not limited to, cyclopropyl, cyclopentyl, and cyclobutyl. Cycloalkyl groups may be substituted or unsubstituted.
[0061] "Spiroalkyl" refers to a polycyclic group with 5 to 18 members, two or more cyclic structures, and one carbon atom (called spiro atom) shared between the monocyclic rings, containing one or more double bonds in the ring, but no ring has a completely conjugated π electron aromatic system. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. According to the number of spiro atoms shared between the rings, the spiroalkyl group is divided into single spiro, double spiro or multiple spiroalkyl groups, preferably single spiro and double spiroalkyl groups, preferably 4 / 5 members, 4 / 6 members, 5 / 5 members or 5 / 6 members. Non-limiting examples of "spiroalkyl" include, but are not limited to, spiro[4.5]decyl, spiro[4.4]nonyl, spiro[3.5]nonyl, spiro[2.4]heptyl.
[0062] "Fused cycloalkyl" refers to a 5 to 18-membered, all-carbon polycyclic group containing two or more cyclic structures sharing a pair of carbon atoms, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron aromatic system, preferably 6 to 12 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl, preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyl. Non-limiting examples of "fused cycloalkyl" include, but are not limited to: bicyclo[3.1.0]hexyl, bicyclo[3.2.0]hept-1-enyl, bicyclo[3.2.0]heptyl, decahydronaphthyl or tetradecahydrophenanthrenyl,
[0063] "Bridged cycloalkyl" refers to an all-carbon polycyclic group with 5 to 18 members, containing two or more cyclic structures that share two non-directly connected carbon atoms. One or more rings may contain one or more double bonds, but none of the rings have completely conjugated π electrons. It is an aromatic system with preferably 6 to 12 members, more preferably 7 to 10 members. It is preferably 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, bridged cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic, preferably bicyclic, tricyclic, or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of "bridged cycloalkyl" include, but are not limited to: (1s,4s)-bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, (1s,5s)-bicyclo[3.3.1]nonyl, bicyclo[2.2.2]octyl, and (1r,5r)-bicyclo[3.3.2]decyl.
[0064] "Heterocyclyl," "heterocycloalkyl," "heterocycle," or "heterocyclic" are used interchangeably herein to refer to a non-aromatic heterocyclic group in which one or more of the ring atoms is selected from nitrogen, oxygen, or S(O) t (wherein t is selected from 0, 1 or 2) heteroatoms, including monocycles, polycycles, condensed rings, bridged rings and spirocycles. Preferably there are 5 to 7 membered monocycles or 7 to 10 membered bicyclic or tricyclic rings, which may contain 1, 2 or 3 atoms selected from nitrogen, oxygen and / or sulfur. The example of "heterocyclic group" includes but is not limited to morpholinyl, oxetanyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, 2-oxo-piperidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperazine-2-one, 8-oxa-3-aza-bicyclo [3.2.1] octyl, piperazinyl, hexahydropyrimidine.
[0065] The heterocyclic group may be substituted or unsubstituted.
[0066] "Spiro heterocyclyl" refers to a polycyclic group with 5 to 18 members, two or more ring structures, and one atom shared between the rings, containing one or more double bonds in the ring, but no ring has a completely conjugated π electron aromatic system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) t(wherein t is selected from 0, 1 or 2) heteroatoms, and the remaining ring atoms are carbon. Preferably 7 to 14 members. According to the number of shared spiro atoms between rings, spiroalkyl is divided into monospiro heterocyclic group, bispiro heterocyclic group or polyspiro heterocyclic group, preferably monospiro heterocyclic group and bispiro heterocyclic group. Monospiro heterocyclic group is preferably 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan monospiro heterocyclic group, and bispiro heterocyclic group is preferably 3 yuan / 4 yuan / 6 yuan, 3 yuan / 4 yuan / 4 yuan or 3 yuan / 4 yuan / 5 yuan bispiro heterocyclic group. Non-limiting examples of "spiro heterocyclic group" include but are not limited to: 1,7-dioxaspiro [4.5] decyl, 2-oxa-7-azaspiro [4.4] nonyl, 7-oxaspiro [3.5] nonyl, 5-oxaspiro [2.4] heptyl,
[0067] "Fused heterocyclic group" refers to a polycyclic group containing two or more ring structures sharing a pair of atoms, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π-electron aromatic system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) t (wherein t is selected from 0, 1 or 2) heteroatom, and the remaining ring atoms are carbon. Preferably it is 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups, preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic groups. Non-limiting examples of "fused heterocyclic groups" include, but are not limited to: octahydropyrrolo[3,4-c]pyrrolyl, octahydro-1H-isoindolyl, 3-azabicyclo[3.1.0]hexyl, octahydrobenzo[b][1,4]dioxin,
[0068] "Bridged heterocyclic group" refers to a 5- to 14-membered, 5- to 18-membered polycyclic group containing two or more ring structures that share two atoms that are not directly connected to each other, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π-electron aromatic system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) t (wherein t is selected from 0, 1 or 2) heteroatoms, and the remaining ring atoms are carbon. Preferably it is 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of "bridged heterocyclic groups" include, but are not limited to: 2-azabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.2]octyl, 2-azabicyclo[3.3.2]decyl,
[0069] "Aryl" refers to a carbocyclic aromatic system containing one or two rings, wherein the rings may be joined together in a fused manner. The term "aryl" includes monocyclic or bicyclic aromatic groups, such as phenyl, naphthyl, tetrahydronaphthyl aromatic groups. Preferably, aryl is C6-C 10 The aryl group is more preferably phenyl and naphthyl, and most preferably naphthyl. The aryl group may be substituted or unsubstituted.
[0070] "Heteroaryl" refers to an aromatic 5- to 6-membered monocyclic or 8- to 10-membered bicyclic ring which may contain 1 to 4 atoms selected from nitrogen, oxygen, and / or sulfur. Examples of "heteroaryl" include, but are not limited to, furanyl, pyridyl, 2-oxo-1,2-dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzodioxolyl, benzothienyl, benzimidazolyl, indolyl, isoindolyl, 1,3-dioxo-isoindolyl, quinolinyl, indazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, isothiazolyl, 1H-1,2,4-triazolyl, 4H-1,2,4 -triazolyl, pyridinyl, pyrimidinyl, pyrazin-2(1H)-onyl, pyrimidin-4(3H)-onyl, pyridazin-3(2H)-onyl, 1H-indolyl, 1H-benzo[d]imidazolyl, 1H-pyrrolo[2,3-c]pyridinyl, 3H-imidazo[4,5-c]pyridinyl, isoquinolinyl, quinazolinyl, 2H-isoindolyl, furo[3,2-b]pyridinyl, furo[2,3-c]pyridinyl, thieno[2,3-c]pyridinyl, benzofuranyl, benzo[b]thienyl, 1H-pyrrolo[3,2-b]pyridinyl, 2H-pyrrolo[3,4-c]pyridinyl.
[0071] Heteroaryl groups can be substituted or unsubstituted.
[0072] "Alkoxy" refers to a group (alkyl-O-). Alkyl is defined herein. C1-C6 alkoxy groups are preferred. Examples include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, and tert-butoxy.
[0073] "Nitro" refers to a -NO2 group.
[0074] "Hydroxy" refers to an -OH group.
[0075] "Halogen" refers to fluorine, chlorine, bromine and iodine.
[0076] "Amino" refers to -NH2.
[0077] "Cyano" refers to -CN.
[0078] "Benzyl" refers to -CH2-phenyl.
[0079] "Carboxyl" refers to -C(O)OH.
[0080] "Carboxylate" refers to a -C(O)O-alkyl group or a -C(O)O-cycloalkyl group, wherein alkyl and cycloalkyl are as defined above.
[0081] "Hydroxyalkyl" refers to an alkyl group substituted with a hydroxy group, wherein alkyl is as defined above.
[0082] "Aminoalkyl" refers to an alkyl group substituted with an amino group, wherein alkyl is as defined above.
[0083] "Haloalkyl" refers to an alkyl group substituted with a halogen, wherein alkyl is as defined above.
[0084] "Haloalkoxy" refers to an alkoxy group substituted with a halogen group, wherein alkoxy is as defined above.
[0085] "DMSO" refers to dimethyl sulfoxide.
[0086] "BOC" refers to tert-butoxycarbonyl.
[0087] "THP" refers to 2-tetrahydropyranyl.
[0088] "TFA" refers to trifluoroacetic acid.
[0089] "Leaving group", or leaving group, is an atom or functional group that breaks away from a larger molecule in a chemical reaction. It is a term used in nucleophilic substitution reactions and elimination reactions. In a nucleophilic substitution reaction, the reactant attacked by the nucleophile is called the substrate, and the atom or group of atoms that breaks away from the substrate molecule with a pair of electrons is called the leaving group. Groups that easily accept electrons and have a strong ability to withstand negative charges are good leaving groups. The smaller the pKa of the conjugate acid of the leaving group, the easier it is for the leaving group to break away from other molecules. The reason is that when the pKa of its conjugate acid is smaller, the corresponding leaving group does not need to bind to other atoms, and the tendency to exist as an anion (or an electrically neutral leaving group) is enhanced. Common leaving groups include but are not limited to halogens, methylsulfonyl, -OTs or -OH.
[0090] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms, in a group are replaced independently of one another by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and a person skilled in the art can determine (by experiment or theory) which substitutions are possible or impossible without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (e.g., olefinic) bond.
[0091] As used herein, "substituted" or "substituted", unless otherwise specified, means that a group may be substituted by one or more groups selected from the following groups: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, amino, haloalkyl, hydroxyalkyl, carboxyl, carboxylate, =O, -OR 5 、-C(O)R 5 、-C(O)OR 5 、-NHC(O)R 5 、-NHC(O)OR 5 、-NR 6 R 7 、-C(O)NR 6 R 7 、-CH2NHC(O)OR 5 、-CH2NR 6 R 7 or -S(O) r R 5 substituted by a substituent;
[0092] R 5 Each is independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted by one or more hydroxyl groups, halogen groups, nitro groups, cyano groups, alkyl groups, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyl groups, heterocyclic groups, aryl groups, heteroaryl groups, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent;
[0093] R 6 and R 7 Each is independently selected from hydrogen, hydroxy, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent;
[0094] Or, R 6 and R 7 Together with the atoms to which they are attached, they form a 4- to 8-membered heterocyclic group, wherein the 4- to 8-membered heterocyclic group contains one or more N, O, or S(O)r, and the 4- to 8-membered heterocyclic group is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic group, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent;
[0095] R 8 、R 9 and R 10 Each is independently selected from hydrogen, alkyl, amino, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted with one or more substituents selected from hydroxy, halogen, nitro, amino, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxyl or carboxylate; r is selected from 0, 1 or 2;
[0096] The compounds of the present invention may contain asymmetric centers or chiral centers and therefore exist in different stereoisomeric forms. It is contemplated that all stereoisomeric forms of the compounds of the present invention, including but not limited to diastereomers, enantiomers and atropisomers and geometric (conformational) isomers and mixtures thereof, such as racemic mixtures, are within the scope of the present invention.
[0097] Unless otherwise indicated, structures depicted herein also encompass all isomers (e.g., diastereoisomers, enantiomers, and atropisomers, and geometric (conformational) isomeric forms of such structures; for example, R and S configurations at various asymmetric centers, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, individual stereoisomers as well as enantiomeric mixtures, diastereomeric mixtures, and geometric (conformational) isomeric mixtures of the present compounds are within the scope of the invention.
[0098] "Pharmaceutically acceptable salts" refer to salts of the above compounds that retain their original biological activity and are suitable for pharmaceutical use. Pharmaceutically acceptable salts of the compounds represented by general formula (I) may be metal salts or amine salts formed with suitable acids.
[0099] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredients and thereby exerting their biological activity.
[0100] Synthesis method of the compound of the present invention
[0101] In order to achieve the purpose of the present invention, the present invention adopts the following technical solutions:
[0102] The present invention provides a method for preparing a compound of formula (II-1) and a compound of formula (II-2) or their stereoisomers, tautomers or pharmaceutically acceptable salts thereof, the method comprising:
[0103] Method 1:
[0104] Compound (IA) reacts with compound (IB) to obtain compound (IC), which then reacts with compound (ID) to produce compound (II-1).
[0105] in:
[0106] X represents a hydroxyl group or a chlorine group;
[0107] W 1 represents fluorine, chlorine, bromine or iodine;
[0108] G, X1, X2, Y1, Y2, Y3, R 1 ~R 4 or L1 is as defined in the general formula (II-1).
[0109] Method 2:
[0110] Compound (IIA) reacts with compound (IIB) to obtain compound of formula (IIC), and compound (IIC) reacts with compound (ID) to produce compound (II-2).
[0111] in:
[0112] X represents a hydroxyl group or a chlorine group;
[0113] W 1 represents fluorine, chlorine, bromine or iodine;
[0114] G, X1, X2, Y1, Y2, Y3, R 1 ~R 4 or L1 is as defined in the general formula (II-2). DETAILED DESCRIPTION
[0115] The present invention is further described below with reference to the following examples, but these examples are not intended to limit the scope of the present invention.
[0116] Example
[0117] The examples provide the preparation of representative compounds represented by formula (I) and related structural identification data. It must be noted that the following examples are used to illustrate the present invention rather than to limit the present invention. 1 H NMR spectra were obtained using a Bruker instrument (400 MHz), and chemical shifts are expressed in ppm using tetramethylsilane as an internal standard (0.00 ppm). 1 H NMR notation: s = singlet, d = doublet, t = triplet, m = multiplet, br = broadened, dd = doublet of a doublet, dt = doublet of a triplet. Coupling constants, when given, are given in Hz.
[0118] Mass spectra were obtained using LC / MS, and the ionization method could be ESI or APCI.
[0119] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The specification of the silica gel plate used in thin layer chromatography (TLC) is 0.15mm~0.2mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm~0.5mm.
[0120] Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
[0121] In the following examples, unless otherwise indicated, all temperatures are in degrees Celsius. Unless otherwise indicated, various starting materials and reagents are commercially available or synthesized according to known methods. Commercially available raw materials and reagents are used directly without further purification, unless otherwise indicated. Commercial manufacturers include but are not limited to Aldrich Chemical Company, ABCR GmbH & Co. KG, Acros Organics, Guangzan Chemical Technology Co., Ltd. and Jingyan Chemical Technology Co., Ltd.
[0122] CD3OD: deuterated methanol.
[0123] CDCl3: deuterated chloroform.
[0124] DMSO-d6: deuterated dimethyl sulfoxide.
[0125] Argon atmosphere means that the reaction bottle is connected to an argon balloon with a capacity of about 1 L.
[0126] Unless otherwise specified in the examples, the solution in the reaction refers to an aqueous solution.
[0127] The compound was purified using silica gel column chromatography and reverse phase column chromatography, with the eluent system selected from: A: petroleum ether and ethyl acetate; B: dichloromethane and methanol; C: dichloromethane: ethyl acetate; and D: aqueous trifluoroacetic acid and acetonitrile. The volume ratio of the solvents varied depending on the polarity of the compound and could be adjusted by adding a small amount of an acidic or alkaline reagent, such as acetic acid or triethylamine.
[0128] Example 1
[0129] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropan]-8-yl)benzamide
[0130] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-yl)benzamide
[0131] first step
[0132] benzyl(1R,5S)-3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate
[0133] (1R,5S)-3-Oxo-8-azabicyclo[3.2.1]octane-8-carboxylic acid benzyl ester
[0134] (1R,5S)-8-azabicyclo[3.2.1]octan-3-one 1a (5 g, 30.94 mmol, commercially available) was dissolved in tetrahydrofuran (125 mL). Potassium carbonate (21.38 g, 154.68 mmol) was added, and the mixture was cooled to 0°C. Benzyl chloroformate (6.33 g, 37.12 mmol) was slowly added dropwise. After the addition was complete, the mixture was allowed to return to room temperature and react for 2 hours. After the reaction was complete, water (30 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: System A) to obtain (1R,5S)-3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylic acid benzyl ester 1b (7.48 g) in a 93% yield.
[0135] MS m / z(ESI):260.1[M+1] +
[0136] Step 2
[0137] benzyl(1R,5S)-3-methylene-8-azabicyclo[3.2.1]octane-8-carboxylate
[0138] (1R,5S)-3-Methylene-8-azabicyclo[3.2.1]octane-8-carboxylic acid benzyl ester
[0139] At room temperature, diethyl ether (250 mL), methyltriphenylphosphonium bromide (41.22 g, 115.39 mmol) and potassium tert-butoxide (12.95 g, 115.39 mmol) were added to a three-necked flask respectively. The mixture was stirred at room temperature for 20 minutes, then heated to 35°C for 1 hour. Subsequently, a diethyl ether solution (100 mL) of (1R,5S)-3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylic acid benzyl ester 1b (7.48 g, 28.85 mmol) was added and the mixture was reacted at 35°C for 12 hours. After the reaction was complete, the reaction solution was filtered through celite, and the filtrate was washed with water (30 mL) and saturated sodium chloride solution (30 mL), respectively. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent: System A) to obtain the product (1R,5S)-3-methylene-8-azabicyclo[3.2.1]octane-8-carboxylic acid benzyl ester 1c (5.1 g) in a yield of 68%.
[0140] MS m / z(ESI):258.2[M+1] +
[0141] Step 3
[0142] benzyl(1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-carboxylate
[0143] (1R,5S)-8-Azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-carboxylic acid benzyl ester
[0144] Under nitrogen, dichloromethane (30 mL) was cooled to 0°C, and diethylzinc (1 M, 25.7 mL) was added dropwise. After stirring, a dichloromethane solution (3 mL) of trifluoroacetic acid (2.92 g, 25.65 mmol) was added dropwise. The mixture was reacted for 30 minutes. A dichloromethane solution (15 mL) of diiodomethane (13.74 g, 51.30 mmol) was added and the mixture was reacted for 30 minutes. Finally, a dichloromethane solution (30 mL) of (1R,5S)-3-methylene-8-azabicyclo[3.2.1]octane-8-carboxylic acid benzyl ester 1c (3.3 g, 12.78 mmol) was added and the mixture was reacted at 25°C for 16 hours. The reaction solution was diluted with dichloromethane (50 mL), quenched by pouring into saturated sodium bicarbonate solution (50 mL), filtered, and the filter cake was washed with dichloromethane (50 mL). The filtrate was separated, and the aqueous phase was extracted with dichloromethane (50 mL × 3). The organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated and purified by silica gel column chromatography (eluent: System A) to give (1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-carboxylic acid benzyl ester 1d (2.37 g) in a yield of 68%.
[0145] MS m / z(ESI):272.2[M+1]+
[0146] Step 4
[0147] (1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]
[0148] (1R,5S)-8-Azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]
[0149] Benzyl (1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-carboxylate 1d (600 mg, 2.21 mmol) was dissolved in methanol (20 mL), and palladium on carbon (120 mg, 20% wt) was added. The mixture was stirred under a hydrogen atmosphere for 16 hours. After the reaction was complete, the mixture was filtered through celite, and the filtrate was concentrated at low temperature to afford (1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane] 1e (300 mg) in a 98% yield.
[0150] MS m / z(ESI):138.2[M+1] +
[0151] Step 5
[0152] 4-iodo-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropan]-8-yl)benzoic acid
[0153] 4-Iodo-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-yl)benzoic acid
[0154] 2-Fluoro-4-iodobenzoic acid 1f (530 mg, 1.99 mmol) and (1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane] 1e (300 mg, 2.19 mmol) were dissolved in dimethyl sulfoxide (8 mL), potassium carbonate (551 mg, 3.98 mmol) was added, and the mixture was reacted at 140°C under a nitrogen atmosphere for 80 hours. The reaction solution was diluted with water (10 mL) and washed once with ethyl acetate (20 mL). The pH of the aqueous phase was adjusted to neutral with acetic acid and extracted with ethyl acetate (20 mL × 3). The combined organic phases were washed sequentially with water (20 mL) and saturated sodium chloride solution (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated and purified by silica gel column chromatography (eluent: System A) to obtain 1 g (378 mg) of 4-iodo-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-yl)benzoic acid in a yield of 49%.
[0155] MS m / z(ESI):384.0[M+1] +
[0156] Step 6
[0157] 4-iodo-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropan]-8-yl)benzoyl chloride
[0158] 4-Iodo-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-yl)benzoyl chloride
[0159] Dissolve 1g (250mg, 0.65mmol) of 4-iodo-2-(1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-yl)benzoic acid in dichloromethane (10mL). Add 1 drop of N,N-dimethylformamide as a catalyst. Add oxalyl chloride (0.16mL, 1.95mmol) under a nitrogen atmosphere and allow to react at room temperature for 1 hour. After removing the solvent and excess oxalyl chloride from the reaction mixture under reduced pressure, 1h (250mg) of 4-iodo-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-yl)benzoyl chloride was obtained, which was used directly in the next reaction.
[0160] Step 7
[0161] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-iodo-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropan]-8-yl)benzamide
[0162] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-iodo-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-yl)benzamide
[0163] To a double-necked flask was added 4-iodo-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-yl)benzoyl chloride 1h (250 mg) from the previous step, and dichloromethane (5 mL) was added for dissolution. Potassium phosphate (413 mg, 1.95 mmol) was added under a nitrogen atmosphere, and then a dichloromethane solution (5 mL) of 2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-amine 1i (155 mg, 0.68 mmol, prepared according to patent WO2021026101A1) and N,N-diisopropylethylamine (0.3 mL, 1.76 mmol) was added dropwise. After the addition was complete, the mixture was reacted at room temperature for 3 days. The reaction mixture was diluted with dichloromethane (20 mL) and washed sequentially with water (20 mL) and saturated sodium chloride solution (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent: System A) to obtain N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-iodo-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-yl)benzamide 1j (56 mg) in a 14% yield. MS m / z (ESI): 594.2 [M+1]. +
[0164] Step 8
[0165] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropan]-8-yl)benzamide
[0166] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-yl)benzamide
[0167] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-iodo-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-yl)benzamide 1j (35 mg, 0.06 mmol), 2-hydroxyethylsulfonamide 1k (11 mg, 0.09 mmol), sarcosine (8.0 mg, 0.09 mmol), cuprous iodide (3.4 mg, 0.018 mmol) and potassium phosphate trihydrate (80 mg, 0.3 mmol) were dissolved in N,N-dimethylformamide (3.0 mL) and reacted at 110°C under nitrogen atmosphere for 5 h. The reaction mixture was cooled to room temperature, ethyl acetate (30 mL) was added to the reaction solution, and the mixture was washed once with water (20 mL) and saturated sodium chloride (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and separated and purified by thin layer chromatography (developing solvent: System A) to give N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,1'-cyclopropane]-8-yl)benzamide 1 (14 mg) with a yield of 36%.
[0168] MS m / z(ESI):591.3[M+1] +
[0169] Example 2
[0170] N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzamide
[0171] N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide
[0172] first step
[0173] (1R,5S)-3-benzyl-8-methylene-3-azabicyclo[3.2.1]octane
[0174] (1R,5S)-3-Benzyl-8-methylene-3-azabicyclo[3.2.1]octane
[0175] Methyltriphenylphosphonium bromide (33.19 g, 92.90 mmol) was dissolved in dry tetrahydrofuran (200 mL). Potassium tert-butoxide (10.42 g, 92.90 mmol) was added at 0°C and stirred for 30 minutes. Then, a solution of (1R, 5S)-3-benzyl-3-azabicyclo[3.2.1]octan-8-one 2a (10 g, 46.45 mmol, commercially available) in tetrahydrofuran (100 mL) was added and the mixture was reacted at 0°C for 1 hour. The reaction solution was quenched with ice water (100 mL) and filtered. The filtrate was extracted with ethyl acetate (200 mL × 3). The organic phase was washed with saturated sodium chloride solution (300 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was separated and purified by silica gel column chromatography (eluent: System A) to give (1R,5S)-3-benzyl-8-methylene-3-azabicyclo[3.2.1]octane 2b (9.2 g) in a yield of 92%.
[0176] MS m / z(ESI):214.2[M+1] +
[0177] Step 2
[0178] (1R,5S)-3-benzyl-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]
[0179] (1R,5S)-3-Benzyl-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]
[0180] Under a nitrogen atmosphere, diethyl ether (25 mL) was cooled to 0°C, and diethyl zinc (1 M, 28.2 mL) was added dropwise. After stirring, a solution of trifluoroacetic acid (3.21 g, 28.13 mmol) in diethyl ether (2 mL) was added dropwise. After stirring for 30 minutes, a solution of diiodomethane (15.07 g, 56.25 mmol) in diethyl ether (15 mL) was added. After stirring for 30 minutes, a solution of (1R, 5S)-3-benzyl-8-methylene-3-azabicyclo[3.2.1]octane 2b (3 g, 14.06 mmol) in diethyl ether (20 mL) was added. The reaction solution was stirred at 25°C for 16 hours. Mass spectrometry indicated completion of the reaction. The reaction solution was diluted with dichloromethane (100 mL) and quenched by pouring into saturated sodium bicarbonate solution (200 mL). The mixture was filtered, the filtrate separated, and the aqueous phase was extracted with dichloromethane (100 mL x 2). The combined organic phases were washed with saturated sodium chloride solution (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by reverse-phase column chromatography (eluent: System D) to obtain (1R,5S)-3-benzyl-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane] 2c (2.35 g) in a 73% yield. MS m / z (ESI): 228.3 [M+1]+
[0181] Step 3
[0182] (1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]
[0183] (1R,5S)-3-Azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]
[0184] (1R,5S)-3-Benzyl-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane] 2c (2.61 g, 11.48 mmol) was dissolved in methanol (25 mL), and palladium on carbon (520 mg, 20% wt) was added. The mixture was stirred under a hydrogen atmosphere for 48 hours. The reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated under reduced pressure to afford (1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane] 2d (1.54 g) in a 97% yield.
[0185] MS m / z(ESI):138.2[M+1]+
[0186] Step 4
[0187] 4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzoic acid
[0188] 4-Iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzoic acid
[0189] Add 2-fluoro-4-iodobenzoic acid 1f (2.3 g, 8.65 mmol), (1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane] 2d (1.42 g, 10.38 mmol), potassium carbonate (2.39 g, 17.29 mmol), and N,N-dimethylformamide (25 mL) to a sealed tube. The reaction was incubated at 125°C under a nitrogen atmosphere for 60 hours. The reaction was monitored by LCMS. Half of the starting material still remained. The reaction solution was diluted with water (100 mL). The aqueous phase was washed once with ethyl acetate (100 mL). The pH of the aqueous phase was adjusted to weakly acidic with acetic acid. A large amount of starting material precipitated and was recovered by filtration. The filtrate was extracted with ethyl acetate (100 mL×2). The organic phases were combined and washed successively with water (100 mL) and saturated sodium chloride solution (100 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated and purified by silica gel column chromatography (eluent: System A) to give 4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1′-cyclopropane]-3-yl)benzoic acid 2e (766 mg) in a yield of 23%.
[0190] MS m / z(ESI):384.1[M+1] +
[0191] Step 5
[0192] N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzamide
[0193] N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide
[0194] To a single-necked flask, 4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzoic acid 2e (100 mg, 0.26 mmol), N,N-dimethylformamide (5 mL), 3-(4,4-difluoropiperidin-1-yl)-5-methylaniline 2f (71 mg, 0.31 mmol, commercially available), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (119 mg, 0.31 mmol), and N,N-diisopropylethylamine (67 mg, 0.52 mmol) were added. The system was reacted at room temperature for 4.5 hours. The reaction solution was diluted with ethyl acetate (50 mL), washed sequentially with water (50 mL) and saturated sodium chloride solution (50 mL), the organic phase was separated, dried over anhydrous sodium sulfate, and concentrated, and the residue was separated and purified by silica gel column chromatography (eluent: System A) to give 2 g (78 mg) of N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide in a yield of 50%.
[0195] MS m / z(ESI):592.2[M+1] +
[0196] Step 6
[0197] N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzamide
[0198] N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide
[0199] In a single-necked bottle, 2 g (78 mg, 0.13 mmol) of N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide, 2-hydroxyethanesulfonamide 1k (25 mg, 0.2 mmol), sarcosine (18 mg, 0.2 mmol), cuprous iodide (8 mg, 0.04 mmol), potassium phosphate trihydrate (175 mg, 0.66 mmol), N,N-dimethylformamide (3.0 mL) and 1 drop of water as catalyst were added, and the system was reacted at 110 ° C for 5 hours under nitrogen protection. The reaction mixture was diluted with ethyl acetate (30 mL) and washed sequentially with water (30 mL) and saturated sodium chloride solution (30 mL). The organic phase was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by thin-layer chromatography (developing solvent: System A). Purified water was then added for lyophilization to obtain N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide 2 (50 mg) in a 61% yield. MS m / z (ESI): 589.3 [M+1]. +
[0200] Example 3
[0201] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-(( 1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzamide
[0202] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide
[0203] first step
[0204] 4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzoyl chloride
[0205] 4-Iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzoyl chloride
[0206] To a single-necked flask, add 4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzoic acid 2e (666 mg, 1.74 mmol), dry dichloromethane (10 mL), and one drop of N,N-dimethylformamide. Oxalyl chloride (0.44 mL, 5.21 mmol) was added dropwise under nitrogen. The mixture was allowed to react at room temperature for 1 hour. The reaction solution was concentrated to afford 4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzoyl chloride 3a (700 mg), which was used directly in the next reaction.
[0207] Step 2
[0208] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzamide
[0209] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide
[0210] Add dry dichloromethane (20 mL) to the concentrate to dissolve it. Add potassium phosphate (1.11 g, 5.21 mmol). Under nitrogen, add dropwise a mixture of 2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-amine 1i (475.95 mg, 2.09 mmol) and N,N-diisopropylethylamine (0.91 mL, 5.21 mmol) in dichloromethane (10 mL). After the addition is complete, react at room temperature for 3 days. The reaction was monitored by mass spectrometry. A small amount of product was produced, and a large amount of starting material remained. The reaction solution was diluted with dichloromethane (30 mL), washed successively with water (30 mL) and saturated sodium chloride solution (30 mL). The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide 3b (35 mg) in a yield of 3%.
[0211] MS m / z(ESI):594.2[M+H] +
[0212] Step 3
[0213] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzamide
[0214] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide
[0215] In a single-necked flask, N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide 3b (35 mg, 0.06 mmol), 2-hydroxyethanesulfonamide 1k (11 mg, 0.09 mmol), sarcosine (8 mg, 0.09 mmol), cuprous iodide (3.4 mg, 0.02 mmol), potassium phosphate trihydrate (78 mg, 0.29 mmol), N,N-dimethylformamide (4.0 mL) and 1 drop of water were added as catalyst, and the system was reacted at 110°C for 5 hours under nitrogen protection. The reaction solution was diluted with ethyl acetate (20 mL), washed sequentially with water (10 mL) and saturated sodium chloride solution (10 mL), the organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated and purified by thin layer chromatography (developing solvent: System A). The purified product was lyophilized to give N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide 3 (17 mg) in a yield of 46%.
[0216] MS m / z(ESI):591.3[M+1] +
[0217] Example 4
[0218] N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0219] N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0220] first step
[0221] 4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzoic acid
[0222] 4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzoic acid
[0223] 2-Fluoro-4-iodobenzoic acid 1f (704 mg, 2.65 mmol) and 6-methyl-3-azabicyclo[4.1.0]heptane hydrochloride 4a (467 mg, 3.18 mmol, commercially available) were dissolved in dimethyl sulfoxide (13 mL), and potassium carbonate (914 mg, 6.63 mmol) was added. The reaction was allowed to proceed at 140°C under a nitrogen atmosphere for 16 hours. The reaction solution was diluted with water (30 mL), the pH was adjusted to neutral with acetic acid, and the mixture was extracted with ethyl acetate (50 mL x 2). The organic phase was washed sequentially with water (30 mL) and saturated sodium chloride solution (30 mL). The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated by silica gel column chromatography (eluent: System A) to afford 4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzoic acid 4b (560 mg) in a 59% yield.
[0224] MS m / z(ESI):358.0[M+1] +
[0225] Step 2
[0226] N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0227] N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzamide
[0228] To a single-necked flask, 4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzoic acid 4b (100 mg, 0.28 mmol), N,N-dimethylformamide (5 mL), 3-(4,4-difluoropiperidin-1-yl)-5-methylaniline 2f (76 mg, 0.34 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (128 mg, 0.34 mmol), and N,N-dimethylformamide (72 mg, 0.56 mmol) were added and reacted at room temperature for 4.5 hours. The reaction solution was diluted with ethyl acetate (30 mL), washed successively with water (20 mL) and saturated sodium chloride solution (20 mL). The separated organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzamide 4c (147 mg) in a yield of 92%.
[0229] MS m / z(ESI):566.1[M+1] +
[0230] Step 3
[0231] N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0232] N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0233] In a single-necked flask, N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzamide 4c (147 mg, 0.26 mmol), 2-hydroxyethanesulfonamide 1k (49 mg, 0.39 mmol), sarcosine (35 mg, 0.39 mmol), cuprous iodide (15 mg, 0.08 mmol), potassium phosphate trihydrate (276 mg, 1.04 mmol), N,N-dimethylformamide (8.0 mL), and 1 drop of water were added as catalyst, and the system was reacted at 110 ° C for 5 hours under nitrogen protection. The reaction solution was diluted with ethyl acetate (50 mL), washed sequentially with water (20 mL) and saturated sodium chloride solution (20 mL), and the separated organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by preparative liquid chromatography (separation column AKZONOBEL Kromasil; 250×21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% TFA+H2O, mobile phase B: CH3CN) to give N-(3-(4,4-difluoropiperidin-1-yl)-5-methylphenyl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptane-3-yl)benzamide 4 (23 mg) in a yield of 14%.
[0234] MS m / z(ESI):563.3[M+1] +
[0235] Example 5
[0236] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0237] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0238] first step
[0239] 4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzoyl chloride
[0240] 4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzoyl chloride
[0241] To a single-necked flask, 4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzoic acid 4b (460 mg, 1.29 mmol), dry dichloromethane (10 mL), and one drop of N,N-dimethylformamide were added. Oxalyl chloride (0.33 mL, 3.87 mmol) was added dropwise under nitrogen. The mixture was allowed to react at room temperature for 1 hour. The reaction solution was concentrated to afford 4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzoyl chloride 5a (500 mg), which was used directly in the next step.
[0242] Step 2
[0243] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0244] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzamide
[0245] Add dry dichloromethane (10 mL) to the concentrate. Once dissolved, add potassium phosphate (820 mg, 3.87 mmol). Add a mixture of 2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-amine 1i (353 mg, 1.55 mmol) and N,N-dimethylformamide (0.67 mL, 3.87 mmol) in dichloromethane (10 mL) dropwise under nitrogen. After the addition is complete, react at room temperature for 3 days. Mass spectrometry monitoring showed that some product was generated and a large amount of starting material remained. The reaction solution was diluted with dichloromethane (20 mL) and washed successively with water (30 mL) and saturated sodium chloride solution (20 mL). The separated organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzamide 5b (46 mg) in a yield of 8%.
[0246] MS m / z(ESI):568.2[M+1] +
[0247] Step 3
[0248] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0249] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0250] In a single-necked flask, N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzamide 5b (46 mg, 0.08 mmol), 2-hydroxyethanesulfonamide 1k (15 mg, 0.12 mmol), sarcosine (11 mg, 0.12 mmol), cuprous iodide (5 mg, 0.02 mmol), potassium phosphate trihydrate (108 mg, 0.41 mmol), N,N-dimethylformamide (5.0 mL), and 1 drop of water were added as catalyst, and the system was reacted at 110 ° C for 5 hours under nitrogen protection. The reaction was complete, monitored by mass spectrometry. The reaction solution was diluted with ethyl acetate (20 mL) and washed sequentially with ethyl acetate (20 mL) and saturated sodium chloride solution (10 mL). The separated organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by thin-layer chromatography (developing solvent: System A). The purified product was lyophilized to obtain N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptane-3-yl)benzamide 5 (31 mg) in a 64% yield. MS m / z (ESI): 565.2 [M+1]. +
[0251] Example 6
[0252] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzamide
[0253] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide
[0254] first step
[0255] 4-nitro-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzoic acid
[0256] 4-Nitro-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzoic acid
[0257] 2-Fluoro-4-nitrobenzoic acid 6a (600 mg, 3.24 mmol, commercially available) and (1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane] hydrochloride 6b (672 mg, 3.88 mmol, commercially available) were dissolved in dimethyl sulfoxide (13 mL), potassium carbonate (1.11 g, 8.1 mmol) was added, and the mixture was reacted at 140°C under a nitrogen atmosphere for 7.5 hours. The reaction mixture was diluted with water (20 mL) and neutralized with 1 M dilute hydrochloric acid. The aqueous phase was extracted with ethyl acetate (20 mL x 3). The organic phase was washed with saturated sodium chloride solution (20 mL), separated, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to afford 4-nitro-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzoic acid 6c (907 mg) in a 92% yield. MS m / z (ESI): 303.2 [M+H]. +
[0258] Step 2
[0259] 7-bromo-5-nitro-2,3-dihydrobenzofuran
[0260] 7-Bromo-5-nitro-2,3-dihydrobenzofuran
[0261] 5-Nitro-2,3-dihydrobenzofuran 6d (7.9 g, 47.87 mmol, commercially available) was dissolved in trifluoroacetic acid (24 mL), and N-bromosuccinimide (10.22 g, 57.44 mmol) and concentrated sulfuric acid (0.26 mL, 4.78 mmol) were added. The mixture was allowed to react at room temperature for 1 hour. Water (120 mL) was added dropwise in an ice bath, and stirring was continued for 2 hours. The mixture was filtered, rinsed with water (100 mL), and the filter cake was collected and dried under vacuum to afford 7-bromo-5-nitro-2,3-dihydrobenzofuran 6e (10.6 g, 90.7% yield).
[0262] Step 3
[0263] 4,4-difluoro-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)piperidine
[0264] 4,4-Difluoro-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)piperidine
[0265] 7-Bromo-5-nitro-2,3-dihydrobenzofuran 6e (10.0 g, 40.98 mmol) was dissolved in toluene (200 mL). 4,4-Difluoropiperidine (9.68 g, 61.47 mmol), palladium acetate (920 mg, 4.1 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (2.37 g, 4.1 mmol), and cesium carbonate (40.0 g, 122.94 mmol) were added and reacted at 90°C under a nitrogen atmosphere overnight. The reaction mixture was filtered through a pad of Celite, and the filtrate was diluted with water (200 mL). The pH of the system was adjusted to 2 with 1 M dilute hydrochloric acid, and the mixture was stirred for 1 hour. The layers were separated, and the organic phase was washed with saturated brine (150 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give the product 4,4-difluoro-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)piperidine 6f (8.5 g) in a yield of 73%.
[0266] Step 4
[0267] 7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-amine hydrochloride
[0268] 7-(4,4-Difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-amine hydrochloride
[0269] 4,4-Difluoro-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)piperidine 6f (8.0 g, 28.16 mmol) was dissolved in methanol (160 mL), and di-tert-butyl dicarbonate (12.28 g, 56.32 mmol) and 10% palladium on carbon (1.6 g) were added. The mixture was allowed to react overnight at room temperature under a hydrogen atmosphere. LCMS confirmed the reaction was complete. The reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated. To the residue was added a 4M solution of hydrogen chloride in ethanol (60 mL) and stirred for 4 hours. The reaction mixture was concentrated, ethyl acetate (150 mL) was added, and the mixture was stirred for 1 hour. The mixture was filtered, the filter cake was collected, and vacuum dried to obtain 6 g (8.7 g) of 7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-amine hydrochloride in a yield of 100.6%.
[0270] Step 5
[0271] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-nitro-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzamide
[0272] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-nitro-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide
[0273] 4-Nitro-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzoic acid 6c (132 mg, 0.43 mmol) was dissolved in N,N-dimethylformamide (5 mL), and 7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-amine hydrochloride 6 g (111 mg, 0.43 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (199 mg, 0.52 mmol), and N,N-diisopropylethylamine (112 mg, 0.87 mmol) were added and reacted at room temperature for 2 hours. LCMS monitoring showed that the reaction of the raw material was complete. The reaction solution was diluted with ethyl acetate (20 mL), washed successively with water (20 mL) and saturated brine (20 mL). The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give the product N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-nitro-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide 6h (202 mg) in a yield of 85%.
[0274] MS m / z(ESI):539.3[M+H] +
[0275] Step 6
[0276] 4-amino-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzamide
[0277] 4-amino-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide
[0278] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-nitro-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide 6h (202 mg, 0.37 mmol) was dissolved in ethanol (10 mL) and water (5 mL). Iron powder (101 mg, 1.85 mmol) and ammonium chloride (39 mg, 0.74 mmol) were added and reacted at 85°C for 3 hours. LCMS monitoring confirmed the complete reaction of the starting material. The reaction solution was filtered through a pad of celite, the filter cake was washed with ethyl acetate, and the organic phase was concentrated to give the product 4-amino-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide 6i (178 mg, yield: 93%).
[0279] MS m / z(ESI):509.3[M+H] +
[0280] Step 7
[0281] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzamide
[0282] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide
[0283] 4-Amino-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide 6i (178 mg, 0.34 mmol) was dissolved in dichloromethane (10 mL). Triethylamine (106.24 mg, 1.05 mmol) and ethylsulfonyl chloride 6j (67 mg, 0.52 mmol) were added and reacted at room temperature under a nitrogen atmosphere for 3 hours. LCMS monitoring confirmed the complete reaction. The reaction solution was diluted with dichloromethane (20 mL), washed with water (20 mL) and saturated brine (20 mL) in sequence, the organic phase was separated, dried over anhydrous sodium sulfate, and concentrated, the residue was dissolved in methanol (1 mL), tetrahydrofuran (1 mL) and water (2 mL), sodium hydroxide (14 mg, 0.37 mmol) was added, and the reaction was carried out at room temperature for 2 hours. The reaction solution was diluted with ethyl acetate (20 mL), washed sequentially with water (20 mL) and saturated brine (20 mL), the organic phase was separated, dried over anhydrous sodium sulfate, and concentrated, and the residue was purified by preparative liquid chromatography (separation column AKZONOBEL Kromasil; 250×21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% TFA+H2O, mobile phase B: CH3CN) to give the product N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1′-cyclopropane]-3-yl)benzamide (88 mg) in a yield of 39%.
[0284] 1 H NMR (400MHz, CDCl3) δ10.88 (s, 1H), 8.13 (d, J = 8.6Hz, 1H), 7.39 (s, 1H), 7.30 (s, 1H) ),6.99(d,J=8.3Hz,1H),6.89(s,1H),6.75(s,1H),4.63(t,J=8.9Hz,2H),3.26-3. 12(m,10H),3.05(d,J=10.2Hz,2H),2.14(s,4H),1.93(s,2H),1.84(d,J=7.4Hz,2H ),1.48(s,2H),1.39(t,J=7.7Hz,3H),0.68(d,J=7.0Hz,2H),0.43(d,J=6.6Hz,2H).
[0285] MS m / z(ESI):601.3[M+H] +
[0286] Example 7
[0287] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0288] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0289] first step
[0290] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0291] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0292] 4-Iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzoic acid 4b (300 mg, 0.83 mmol) was dissolved in N,N-dimethylformamide (5 mL), and 7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-amine hydrochloride 6 g (213 mg, 0.83 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (383 mg, 1.01 mmol) and N,N-diisopropylethylamine (217 mg, 1.68 mmol) were added and reacted at room temperature for 2 hours. LCMS monitoring indicated that the reaction of the starting material was complete. The reaction solution was diluted with ethyl acetate (20 mL), washed sequentially with water (20 mL) and saturated brine (20 mL). The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give the product N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]heptane-3-yl)benzamide 7a (371 mg) in a yield of 74%.
[0293] MS m / z(ESI):594.2[M+H] +
[0294] Step 2
[0295] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0296] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0297] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]heptane-3-yl)benzamide 7a (371 mg, 0.63 mmol) and ethylsulfonamide 7b (102 mg, 0.93 mmol) were dissolved in N,N-dimethylformamide (10 mL), sarcosine (83 mg, 0.93 mmol), cuprous iodide (35 mg, 0.18 mmol), potassium phosphate trihydrate (831 mg, 3.13 mmol) and reacted at 110 ° C under nitrogen atmosphere for 5 hours. LCMS monitoring showed that the reaction of the raw material was complete. The reaction solution was diluted with ethyl acetate (20 mL), washed successively with water (20 mL) and saturated brine (20 mL). The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give the product N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptane-3-yl)benzamide 7 (216 mg) in a yield of 57%.
[0298] 1H NMR (400MHz, DMSO-d6) δ10.87(s,1H),10.05(s,1H),7.65(d,J=8.4Hz,1H),7.25(s,1H),7.16(s,1H),7.01(d,J =1.6Hz,1H),6.95(dd,J=8.4,1.6Hz,1H),4.53(t,J=8.7Hz,2H),3.31(m,1H),3.16(dd,J=12.4,5.6Hz,8H),3.00 -2.91(m,1H),2.75(ddd,J=12.3,10.1,5.6Hz,2H),2.15-2.01(m,4H),1.83(ddd,J=20.8,14.2,8.1Hz,2H),1.20 (t,J=7.4Hz,3H),1.09(s,3H),0.99(dd,J=13.1,6.2Hz,1H),0.58(t,J=4.5Hz,1H),0.44(dd,J=8.6,4.0Hz,1H).
[0299] MS m / z(ESI):575.3[M+H] +
[0300] Example 8
[0301] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-(ethylsulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0302] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-(ethylsulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0303] first step
[0304] 4,4-difluoro-1-(2-methoxy-5-nitrophenyl)piperidine
[0305] 4,4-Difluoro-1-(2-methoxy-5-nitrophenyl)piperidine
[0306] 2-Bromo-1-methoxy-4-nitrobenzene 8a (2.0 g, 8.62 mmol) was dissolved in toluene (20 mL), and 4,4-difluoropiperidine (1.25 g, 10.34 mmol), tris(dibenzylideneacetone)dipalladium (395 mg, 0.43 mmol), 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (537 mg, 0.86 mmol), and sodium tert-butoxide (1.66 g, 17.24 mmol) were added and reacted at 110 °C under nitrogen atmosphere for 4 hours. The reaction was complete as monitored by LCMS. The reaction solution was directly concentrated and redissolved in ethyl acetate (50 mL). The mixture was washed sequentially with water (50 mL) and saturated sodium chloride (50 mL). The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to obtain the product, 4,4-difluoro-1-(2-methoxy-5-nitrophenyl)piperidine 8b (1.25 g), in a 53% yield. MS m / z (ESI): 273.1 [M+H]. +
[0307] Step 2
[0308] 3-(4,4-difluoropiperidin-1-yl)-4-methoxyaniline
[0309] 3-(4,4-difluoropiperidin-1-yl)-4-methoxyaniline
[0310] 4,4-Difluoro-1-(2-methoxy-5-nitrophenyl)piperidine 8b (1.2 g, 4.41 mmol) was dissolved in methanol (10 mL) and 10% palladium on carbon (120 mg) was added. The mixture was allowed to react at room temperature under a hydrogen atmosphere for 8 hours. LCMS confirmed the reaction was complete. The reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to afford 3-(4,4-difluoropiperidin-1-yl)-4-methoxyaniline 8c (934 mg, 87% yield).
[0311] MS m / z(ESI):243.1[M+H] +
[0312] Step 3
[0313] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept an-3-yl)benzamide
[0314] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0315] 4-Iodo-2-(6-methyl-3-azabicyclo[4.1.0]hept-3-yl)benzoic acid 4b (150 mg, 0.41 mmol) was dissolved in N,N-dimethylformamide (5 mL), and 3-(4,4-difluoropiperidin-1-yl)-4-methoxyaniline 8c (101 mg, 0.41 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (191 mg, 0.5 mmol), and N,N-diisopropylethylamine (108 mg, 0.83 mmol) were added and reacted at room temperature for 2 hours. LCMS monitoring indicated that the reaction of the starting material was complete. The reaction solution was diluted with ethyl acetate (20 mL), washed sequentially with water (20 mL) and saturated brine (20 mL). The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give the product N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]heptane-3-yl)benzamide 8d (188 mg) in a yield of 76%.
[0316] MS m / z(ESI):582.2[M+H] +
[0317] Step 4
[0318] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-(ethylsulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0319] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-(ethylsulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0320] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-iodo-2-(6-methyl-3-azabicyclo[4.1.0]heptane-3-yl)benzamide 8d (188 mg, 0.32 mmol) and ethylsulfonamide (52.94 mg, 0.48 mmol) were dissolved in N,N-dimethylformamide (5 mL), and sarcosine (43 mg, 0.48 mmol), cuprous iodide (18 mg, 0.097 mmol), and potassium phosphate trihydrate (430 mg, 1.62 mmol) were added, and the mixture was reacted at 110 ° C under a nitrogen atmosphere for 5 hours. LCMS monitoring showed that the reaction of the raw material was complete. The reaction solution was diluted with ethyl acetate (20 mL), washed successively with water (20 mL) and saturated brine (20 mL). The organic phase was separated, dried over anhydrous sodium sulfate, concentrated, and prepared and purified to give the product N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-(ethylsulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptane-3-yl)benzamide 8 (86 mg) in a yield of 44%.
[0321] 1 H NMR (400MHz, DMSO-d6) δ10.87(s,1H),10.06(s,1H),7.65(d,J=8.4Hz,1H),7.42(d,J=2.1Hz,1H),7.31(dd, J=8.7,2.1Hz,1H),7.02(s,1H),6.98-6.90(m,2H),3.79(s,3H),3.35-3.29(m,1H),3.16(q,J=7.3Hz,2H),3. 08(s,4H),2.97(d,J=11.6Hz,1H),2.75(ddd,J=20.2,13.4,6.9Hz,2H),2.19-2.00(m,4H),1.92-1.70(m,2H ),1.20(t,J=7.3Hz,3H),1.09(s,3H),1.02-0.93(m,1H),0.58(t,J=4.4Hz,1H),0.44(dd,J=8.6,4.1Hz,1H).
[0322] MS m / z(ESI):563.3[M+H] +
[0323] Example 9
[0324] N-(6-(4,4-difluoropiperidin-1-yl)-5-methoxypyridin-2-yl)-4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzamide
[0325] N-(6-(4,4-difluoropiperidin-1-yl)-5-methoxypyridin-2-yl)-4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide
[0326] first step
[0327] 2-(4,4-difluoropiperidin-1-yl)-3-methoxy-6-nitropyridine
[0328] 2-(4,4-difluoropiperidin-1-yl)-3-methoxy-6-nitropyridine
[0329] 2-Bromo-3-methoxy-6-nitropyridine 9a (1 g, 4.29 mmol), 4,4-difluoropiperidine (0.78 g, 6.44 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl) palladium (II) (0.18 g, 0.21 mmol), and cesium carbonate (2.8 g, 8.58 mmol) were added to a microwave tube, and 1,4-dioxane (8 mL) was added. The reaction was carried out at 120 ° C under microwave conditions for 1 hour. The reaction was complete by LCMS. After the reaction solution was cooled, it was filtered through a pad of celite. The filter cake was rinsed with ethyl acetate (20 mL). The filtrate was concentrated and the residue was purified by silica gel column chromatography (eluent: System A) to give the product 2-(4,4-difluoropiperidin-1-yl)-3-methoxy-6-nitropyridine 9b (1 g) in a yield of 85.3%.
[0330] MS m / z(ESI):274.1[M+H] +
[0331] Step 2
[0332] 6-(4,4-difluoropiperidin-1-yl)-5-methoxypyridin-2-amine
[0333] 2-Amino-6-(4,4-difluoropiperidin-1-yl)-3-methoxypyridine
[0334] 2-(4,4-difluoropiperidin-1-yl)-3-methoxy-6-nitropyridine 9b (1 g, 3.66 mmol) was dissolved in methanol (15 mL), and 10% palladium on carbon (0.2 g) was added. The mixture was stirred overnight at room temperature under a hydrogen atmosphere. LCMS confirmed the reaction was complete. The reaction mixture was filtered through a pad of Celite, and the filter cake was rinsed with ethyl acetate (20 mL). The filtrate was concentrated, and the residue was purified by silica gel column chromatography (eluent: System A) to afford 2-amino-6-(4,4-difluoropiperidin-1-yl)-3-methoxypyridine 9c (0.5 g) in a 56.2% yield.
[0335] MS m / z(ESI):244.1[M+H] +
[0336] Step 3
[0337] N-(6-(4,4-difluoropiperidin-1-yl)-5-methoxypyridin-2-yl)-4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzamide
[0338] N-(6-(4,4-difluoropiperidin-1-yl)-5-methoxypyridin-2-yl)-4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide
[0339] 4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzoic acid 2e (0.25 g, 0.66 mmol) was dissolved in N,N-dimethylformamide (5 mL), and 2-amino-6-(4,4-difluoropiperidin-1-yl)-3-methoxypyridine 9b (0.16 g, 0.66 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 0.37 g, 0.99 mmol), and diisopropylethylamine (0.26 g, 1.97 mmol) were added, and the mixture was stirred at room temperature overnight. The reaction of the starting material was complete as monitored by LCMS. Saturated brine (30 mL) was added and extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give the product N-(6-(4,4-difluoropiperidin-1-yl)-5-methoxypyridin-2-yl)-4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1′-cyclopropane]-3-yl)benzamide 9d (0.36 g) in a yield of 89.9%.
[0340] MS m / z(ESI):608.9[M+H] +
[0341] Step 4
[0342] N-(6-(4,4-difluoropiperidin-1-yl)-5-methoxypyridin-2-yl)-4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)benzamide
[0343] N-(6-(4,4-difluoropiperidin-1-yl)-5-methoxypyridin-2-yl)-4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide
[0344] N-(6-(4,4-difluoropiperidin-1-yl)-5-methoxypyridin-2-yl)-4-iodo-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide 9d (0.36 g, 0.59 mmol) was dissolved in N,N-dimethylformamide (8 mL), and ethylsulfonamide 7b (96.8 mg, 0.89 mmol), cuprous iodide (33.8 mg, 0.17 mmol), sarcosine (47.4 mg, 0.53 mmol), and potassium phosphate trihydrate (315.1 mg, 1.18 mmol) were added, and the mixture was stirred at 110 °C under a nitrogen atmosphere for 3 hours. LCMS detection showed that the reaction of the raw material was complete, and saturated brine (20 mL) was added, extracted with ethyl acetate (15 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) and then prepared to give the product N-(6-(4,4-difluoropiperidin-1-yl)-5-methoxypyridin-2-yl)-4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)benzamide 9 (122.3 mg) with a yield of 33.3%.
[0345] MS m / z(ESI):590.3[M+H] +
[0346] 1 H NMR (400MHz, DMSO-d6) δ10.67(s,1H),10.10(s,1H),7.84(s,1H),7.73(s,1H),7.35(s,1H),7.21(s,1H),7.02(s,1H),3.81(s,3H),3. 46(m,4H),3.16(q,J=7.3Hz,2H),3.00(m,4H),2.04(m,6H),1.76(s,2H),1.44(s,2H),1.20(t,J=7.3Hz,3H),0.62(s,2H),0.37(s,2H).
[0347] Example 10
[0348] 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-(ethylsulfonamido)benzamide
[0349] 2-(7,7-Difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-(ethylsulfonamido)benzamide
[0350] first step
[0351] 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-4-nitrobenzoic acid
[0352] 2-(7,7-Difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-4-nitrobenzoic acid
[0353] 2-Fluoro-4-nitrobenzoic acid 6a (0.3 g, 1.62 mmol) and 7,7-difluoro-3-azabicyclo[4.1.0]heptane hydrochloride 10a (0.33 g, 1.94 mmol) were dissolved in dimethyl sulfoxide (10 mL). Cesium carbonate (1.06 g, 3.24 mmol) was added, and the mixture was stirred at 140°C for 4 hours. LCMS confirmed the reaction was complete. Saturated brine (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: System A) to afford 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-4-nitrobenzoic acid 10b (0.36 g) in a 75.1% yield.
[0354] MS m / z(ESI):299.1[M+H] +
[0355] Step 2
[0356] 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-nitrobenzamide
[0357] 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-nitrobenzamide
[0358] 3-(4,4-Difluoropiperidin-1-yl)-4-methoxyaniline 8c (0.28 g, 1.14 mmol) and 2-(7,7-difluoro-3-azabicyclo[4.1.0]hept-3-yl)-4-nitrobenzoic acid 10b (0.34 g, 1.14 mmol) were dissolved in N,N-dimethylformamide (8 mL), and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 0.65 g, 1.71 mmol) and diisopropylethylamine (0.44 g, 3.42 mmol) were added, and the mixture was stirred at room temperature overnight. LCMS confirmed the complete reaction of the starting material. Saturated brine (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: System A) to afford 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-nitrobenzamide 10c (0.53 g) in an 89.0% yield. MS m / z (ESI): 622.9 [M+H]. +
[0359] Step 3
[0360] 4-amino-2-(7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)benzamide
[0361] 4-Amino-2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)benzamide
[0362] 2-(7,7-Difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-nitrobenzamide 10c (0.50 g, 0.96 mmol) was dissolved in ethanol (20 mL), 10% palladium on carbon (0.10 g) was added, and the mixture was stirred at room temperature under a hydrogen atmosphere overnight. LCMS detected that the reaction of the starting material was complete. The reaction solution was filtered through a pad of celite, the filter cake was rinsed with methanol (10 mL), and the filtrate was concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give the product 4-amino-2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)benzamide 10d (0.44 g) in a yield of 93.6%.
[0363] MS m / z(ESI):493.2[M+H] +
[0364] Step 4
[0365] 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-(ethylsulfonamido)benzamide
[0366] 2-(7,7-Difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-(ethylsulfonamido)benzamide
[0367] 4-Amino-2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)benzamide 10d (0.20 g, 0.41 mmol) was dissolved in dichloromethane (10 mL), and triethylamine (0.21 g, 2.03 mmol) and ethylsulfonyl chloride 6j (0.21 g, 1.62 mmol) were added, and the mixture was stirred at room temperature for 2 hours. LCMS detection showed that the reaction of the raw material was complete, and saturated brine (30 mL) was added, extracted with ethyl acetate (30 mL×3), and the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: System A) to obtain the product 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-4-(ethylsulfonyl)benzamide 10 (81.3 mg) with a yield of 32.5%.
[0368] MS m / z(ESI):585.2[M+H] +
[0369] 1H NMR (400MHz, DMSO-d6) δ10.87(s,1H),7.71(d,J=8.4Hz,1H),7.38(d,J=2.5Hz,1H),7.29(dd,J=8 .7,2.4Hz,1H),7.03(d,J=2.1Hz,1H),6.98(dd,J=8.4,2.0Hz,1H),6.93(d,J=8.8Hz,1H),3.79(s, 3H),3.44-3.34(m,4H),3.16(q,J=7.3Hz,2H),3.11-3.05(m,4H),3.02(dd,J=12.5,3.1Hz,1H),2 .92-2.81(m,1H),2.76-2.66(m,1H),2.19-2.03(m,4H),1.99-1.80(m,2H),1.20(t,J=7.3Hz,3H).
[0370] Example 11
[0371] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-2-(8-azadispiro[2.1.5 5 .1 3 ]undecan-8-yl)-4-(ethylsulfonamido)benzamide
[0372] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-2-(8-azabispiro[2.1.5 5 .1 3 ]undec-8-yl)-4-(ethylsulfonamido)benzamide
[0373] first step
[0374] 7-azaspiro[3.5]nonan-2-one hydrochloride
[0375] 7-Azaspiro[3.5]nonan-2-one hydrochloride
[0376] Tert-butyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate 11a (24.2 g, 100.3 mmol) was dissolved in dichloromethane (240 mL), and 4 M aqueous hydrochloric acid (120 mL) was added. The mixture was stirred at 15°C for 12 hours. TLC confirmed the complete reaction. The reaction solution was concentrated, petroleum ether (100 mL) was added, and the solid was filtered and dried to obtain 7-azaspiro[3.5]nonan-2-one hydrochloride 11b (17.5 g) in a 99.3% yield.
[0377] Step 2
[0378] benzyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate
[0379] Benzyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate
[0380] 7-Azaspiro[3.5]nonan-2-one hydrochloride 11b (17.5 g, 99.6 mmol) was dissolved in tetrahydrofuran (150 mL), and potassium carbonate (68.84 g, 498.1 mmol) was added. Benzyl chloroformate (20.39 g, 119.6 mmol) was added dropwise under an ice bath. The mixture was warmed to room temperature and stirred for 12 hours. LCMS confirmed the reaction was complete. The mixture was diluted with water (300 mL) and extracted with ethyl acetate (200 mL x 2). The organic phases were combined, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The resulting residue was purified by silica gel column chromatography (eluent: System A) to afford benzyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate 11d (21.37 g) in a 78.4% yield.
[0381] MS m / z(ESI):274.1[M+H] +
[0382] Step 3
[0383] benzyl 2-methylene-7-azaspiro[3.5]nonane-7-carboxylate
[0384] Benzyl 2-methyl-7-azaspiro[3.5]nonane-7-carboxylate
[0385] Methyltriphenylphosphonium bromide 11e (55.86 g, 156.37 mmol) and potassium tert-butoxide (17.55 g, 156.37 mmol) were dissolved in tetrahydrofuran (440 mL) and stirred at room temperature for 30 minutes. Then, a solution of benzyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate 11d (21.37 g, 78.18 mmol) in tetrahydrofuran (210 mL) was added and stirred at room temperature for 4 hours. LCMS monitoring showed that the raw material reaction was complete, and the product was diluted with water (500 mL) and filtered. The filtrate was extracted with ethyl acetate (500 mL×3). The combined organic phases were washed with saturated brine (800 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The resulting residue was purified by silica gel column chromatography (eluent: System A) to give the product, 2-methyl-7-azaspiro[3.5]nonane-7-carboxylic acid benzyl ester 11f (19.5 g), in a yield of 91.91%.
[0386] MS m / z(ESI):272.1[M+H] +
[0387] Step 4
[0388] benzyl 8-azadispiro[2.1.5 5 .1 3 ]undecane-8-carboxylate
[0389] 8-Azabispiro[2.1.5 5 .1 3 Benzyl undecane-8-carboxylate
[0390] Diethylzinc solution (1M, 140 mL) was added to dichloromethane (200 mL) under a nitrogen atmosphere in an ice bath. After stirring, a solution of trifluoroacetic acid (10.40 mL, 140.0 mmol) in dichloromethane (20 mL) was added dropwise. After stirring for 30 minutes, a solution of diiodomethane (75.01 g, 280.1 mmol) in dichloromethane (80 mL) was added dropwise. After reacting for 30 minutes, a solution of 2-methyl-7-azaspiro[3.5]nonane-7-carboxylic acid benzyl ester 11f (19 g, 70.02 mmol) in dichloromethane (200 mL) was added dropwise. The reaction solution was reacted at room temperature for 12 hours. LCMS monitoring showed that the reaction of the raw material was complete. The reaction solution was diluted with dichloromethane (500 mL), poured into a saturated sodium bicarbonate solution (600 mL), filtered, and the filtrate was separated. The aqueous phase was extracted with dichloromethane (400 mL × 2), and the combined organic phases were washed with saturated brine (300 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to obtain the product 8-azabisspiro[2.1.5 5 .1 3]Undecane-8-carboxylic acid benzyl ester 11g (16g), yield: 80.1%.
[0391] MS m / z(ESI):286.2[M+H] +
[0392] Step 5
[0393] 8-azadispiro[2.1.5 5 .1 3 ]undecane
[0394] 8-Azabispiro[2.1.5 5 .1 3 Undecane
[0395] 8-azabispiro[2.1.5 5 .1 3 ] Undecane-8-carboxylic acid benzyl ester 11g (12g, 42.1mmol) was dissolved in methanol (150mL), 10% palladium carbon (1.68g) and palladium hydroxide (1.68g) were added, and the mixture was reacted at room temperature under a hydrogen atmosphere for 6 hours. LCMS monitoring showed that the reaction of the raw material was complete, the reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated to obtain the product 8-azabisspiro[2.1.5 5 .1 3 ]Undecane 11h (5.2 g), yield: 81.8%.
[0396] MS m / z(ESI):152.2[M+H] +
[0397] Step 6 2-(8-azadispiro[2.1.5 5 .1 3 ]undecan-8-yl)-4-iodobenzoic acid
[0398] 2-(8-azabispiro[2.1.5 5 .1 3 ]undec-8-yl)-4-iodobenzoic acid
[0399] 2-Fluoro-4-iodobenzoic acid 1e (0.5 g, 1.88 mmol) and 8-azabispiro[2.1.5 5 .1 3 ] Undecane 11h (0.43 g, 2.82 mmol) was dissolved in dimethyl sulfoxide (15 mL), cesium carbonate (1.22 g, 3.76 mmol) was added, and the mixture was stirred at 140 ° C for 5 hours. LCMS monitored the reaction of the raw materials. After the reaction solution was cooled, it was poured into water, 1M hydrochloric acid was added to adjust the pH to weak acidity, and the product 2-(8-azabisspiro[2.1.55 .1 3 ]undec-8-yl)-4-iodobenzoic acid 11i (0.7 g).
[0400] MS m / z(ESI):398.1[M+H] +
[0401] Step 7
[0402] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-2-(8-azadispiro[2.1.5 5 .1 3 ]undecan-8-yl)-4-iodobenzamide
[0403] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-2-(8-azabispiro[2.1.5 5 .1 3 ]undec-8-yl)-4-iodobenzamide
[0404] 3-(4,4-difluoropiperidin-1-yl)-4-methoxyaniline 8c (0.29 g, 1.21 mmol) and 2-(8-azabispiro[2.1.5 5 .1 3 ] Undecane-8-yl)-4-iodobenzoic acid 11i (0.4 g, 1.01 mmol) was dissolved in N,N-dimethylformamide (15 mL), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.57 g, 1.51 mmol) was added, and diisopropylethylamine (0.39 g, 3.02 mmol) was added, and stirred at room temperature overnight. LCMS monitored the reaction of the raw material, saturated brine (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was chromatographed on a silica gel column (eluent: System A) to give the product N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-2-(8-azadispiro[2.1.5 5 .1 3 ]undec-8-yl)-4-iodobenzamide 11j (0.25 g), yield: 39.5%.
[0405] MS m / z(ESI):622.2[M+H] +
[0406] Step 8
[0407] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-2-(8-azadispiro[2.1.5 5 .1 3 ]undecan-8-yl)-4-(ethylsulfonamido)benzamide
[0408] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-2-(8-azabispiro[2.1.5 5 .1 3 ]undec-8-yl)-4-(ethylsulfonamido)benzamide
[0409] N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-2-(8-azabispiro[2.1,5 5 .1 3 ]Undec-8-yl)-4-iodobenzamide 11j (0.25 g, 0.40 mmol) and ethylsulfonamide 7b (65.1 mg, 0.60 mmol) were dissolved in N,N-dimethylformamide (8 mL), and cuprous iodide (22.7 mg, 0.12 mmol), sarcosine (53.1 mg, 0.60 mmol), and potassium phosphate trihydrate (0.21 g, 0.80 mmol) were added, and the mixture was stirred at 110 ° C for 4 hours under a nitrogen atmosphere. LCMS detected that the reaction of the raw material was complete, saturated brine (20 mL) was added, extracted with ethyl acetate (15 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: System A) and then by preparative liquid chromatography (separation column AKZONOBEL Kromasil; 250 × 21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% TFA + H2O, mobile phase B: CH3CN) to obtain the product N-(3-(4,4-difluoropiperidin-1-yl)-4-methoxyphenyl)-2-(8-azadispiro[2.1.5 5 .1 3 ]undec-8-yl)-4-(ethylsulfonamido)benzamide 11 (32.8 mg), yield: 13.0%.
[0410] MS m / z(ESI):603.3[M+H] +
[0411] 1H NMR (400MHz, DMSO-d6) δ11.61(s,1H),7.82(d,J=8.5Hz,1H),7.49(dd,J=8.7,2.4Hz,1H),7. 22(d,J=2.5Hz,1H),7.09(d,J=2.1Hz,1H),7.01(dd,J=8.5,2.1Hz,1H),6.95(d,J=8.8Hz,1H ),3.79(s,3H),3.15(q,J=7.3Hz,2H),3.06(t,J=5.6Hz,4H),2.86(t,J=5.3Hz,4H),2.09(tt ,J=13.7,5.5Hz,4H),1.89(s,4H),1.84(t,J=5.3Hz,4H),1.19(t,J=7.3Hz,3H),0.40(s,4H).
[0412] Example 12
[0413] 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)benzamide
[0414] 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)benzamide
[0415] first step
[0416] 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-nitrobenzamide
[0417] 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-nitrobenzamide
[0418] 7-(4,4-Difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-amine hydrochloride 6 g (0.23 g, 0.80 mmol) and 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-4-nitrobenzoic acid 10b (0.24 g, 0.80 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.46 g, 1.21 mmol) were dissolved in N,N-dimethylformamide (8 mL), and diisopropylethylamine (0.31 g, 2.41 mmol) was added, and the mixture was stirred at room temperature for 4 hours. The reaction of the starting material was complete as monitored by LCMS. Saturated brine (30 mL) was added and extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: System A) to give the product 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-nitrobenzamide 12a (0.42 g) in a yield of 97.6%.
[0419] MS m / z(ESI):535.2[M+H] +
[0420] Step 2
[0421] 4-amino-2-(7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)benzamide
[0422] 4-Amino-2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)benzamide
[0423] 2-(7,7-Difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-nitrobenzamide 12a (0.42 g, 0.75 mmol) was dissolved in ethanol (10 mL), 10% palladium on carbon (50.3 mg) was added, and the mixture was stirred at room temperature under hydrogen atmosphere for 5 hours. LCMS detected that the reaction of the starting material was complete. The reaction solution was filtered through a pad of celite, and the filtrate was rinsed with dichloromethane (20 mL). The filtrate was concentrated, and the residue was purified by silica gel column chromatography (eluent: System A) to give the product 4-amino-2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)benzamide 12b (0.37 g) in a yield of 98.0%.
[0424] MS m / z(ESI):505.3[M+H] +
[0425] Step 3
[0426] 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)benzamide
[0427] 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)benzamide
[0428] 4-Amino-2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)benzamide 12b (0.10 g, 0.20 mmol) was dissolved in dichloromethane (4 mL). Triethylamine (60.2 mg, 0.59 mmol) and ethylsulfonyl chloride 6j (50.9 mg, 0.40 mmol) were added and stirred at room temperature for 2.5 hours. LCMS confirmed the complete reaction. The mixture was then added with saturated brine (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was dissolved in methanol (8 mL) and water (2 mL). Sodium hydroxide (22.6 mg, 0.56 mmol) was added and stirred at room temperature for 2 hours. The methanol was removed by concentration, and saturated brine (30 mL) was added. The product was extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) and then by preparative liquid chromatography (separation column AKZONOBEL Kromasil; 250×21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% TFA+H2O, mobile phase B: CH3CN) to give the product 2-(7,7-difluoro-3-azabicyclo[4.1.0]heptane-3-yl)-N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)benzamide 12 (52.2 mg) in a yield of 44.0%.
[0429] MS m / z(ESI):597.3[M+H] +
[0430] 1 H NMR (400MHz, DMSO-d6) δ10.77(s,1H),7.69(d,J=8.4Hz,1H),7.27(d,J=1.9Hz,1H),7.0 6(d,J=2.0Hz,1H),7.03(d,J=2.1Hz,1H),6.97(dd,J=8.4,2.0Hz,1H),4.52(t,J=8.7Hz, 2H),3.45-3.34(m,4H),3.22-3.11(m,8H),3.06-2.99(m,1H),2.91-2.81(m,1H),2.75-2 .66(m,1H),2.07(dq,J=13.7,7.1,6.0Hz,4H),1.98-1.81(m,2H),1.20(t,J=7.3Hz,3H).
[0431] Example 13
[0432] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(8-azadispiro[2.1.5 5 .1 3 ]undecan-8-yl)-4-(ethylsulfonamido)benzamide
[0433] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(8-azabispiro[2.1.5 5 .1 3 ]undec-8-yl)-4-(ethylsulfonamido)benzamide
[0434] first step
[0435] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(8-azadispiro[2.1.5 5 .1 3 ]undecan-8-yl)-4-iodobenzamide
[0436] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(8-azabispiro[2.1,5 5 .1 3 ]undec-8-yl)-4-iodobenzamide
[0437] 7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-amine hydrochloride 6g (0.22g, 0.76mmol) and 2-(8-azabispiro[2.1.5 5 .1 3] Undecane-8-yl)-4-iodobenzoic acid 11i (0.30 g, 0.76 mmol) was dissolved in N,N-dimethylformamide (8 mL), and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 0.43 g, 1.13 mmol) and diisopropylethylamine (0.29 g, 2.27 mmol) were added, and stirred at room temperature for 3 hours. LCMS monitored the complete reaction of the raw material, saturated brine (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: System A) to obtain N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(8-azadispiro[2.1.5 5 .1 3 ]undec-8-yl)-4-iodobenzamide 13a (0.4 g), yield: 83.6%.
[0438] MS m / z(ESI):634.2[M+H] +
[0439] Step 2
[0440] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(8-azadispiro[2.1.5 5 .1 3 ]undecan-8-yl)-4-(ethylsulfonamido)benzamide
[0441] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(8-azabispiro[2.1.5 5 .1 3 ]undec-8-yl)-4-(ethylsulfonamido)benzamide
[0442] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(8-azabispiro[2.1.5 5 .1 3]Undec-8-yl)-4-iodobenzamide 13a (0.15 g, 0.24 mmol) was dissolved in N,N-dimethylformamide (8 mL), and ethylsulfonamide 7b (38.8 mg, 0.36 mmol), cuprous iodide (13.5 mg, 0.07 mmol), sarcosine (18.9 mg, 0.23 mmol), and potassium phosphate trihydrate (0.19 g, 0.71 mmol) were added, and the mixture was stirred at 110 ° C under a nitrogen atmosphere for 5 hours. LCMS showed that the reaction of the raw material was complete, and saturated brine (15 mL) was added, extracted with ethyl acetate (15 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) and then by preparative liquid chromatography (separation column AKZONOBEL Kromasil; 250 × 21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% TFA + H2O, mobile phase B: CH3CN) to obtain the product N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(8-azadispiro[2.1.5 5 .1 3 ]undec-8-yl)-4-(ethylsulfonamido)benzamide 13 (43.8 mg), yield 28.6%.
[0443] MS m / z(ESI):615.3[M+H] +
[0444] 1 H NMR (400MHz, DMSO-d6) δ11.51(s,1H),10.16(s,1H),7.80(d,J=8.5Hz,1H),7.51(d, J=1.8Hz,1H),7.09(d,J=2.1Hz,1H),7.01(dd,J=8.5,2.1Hz,1H),6.88(d,J=2.0Hz,1 H),4.53(t,J=8.7Hz,2H),3.21-3.11(m,8H),2.85(t,J=5.3Hz,4H),2.07(tt,J=13.9 ,5.6Hz,4H),1.89(s,4H),1.84(t,J=5.3Hz,4H),1.19(t,J=7.3Hz,3H),0.40(s,4H).
[0445] Example 14
[0446] 2-(4,4-difluoropiperidin-1-yl)-N-(4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)phenyl)pyrimidine-4-carboxamide
[0447] 2-(4,4-difluoropiperidin-1-yl)-N-(4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)phenyl)pyrimidine-4-carboxamide
[0448] first step
[0449] 2-(4,4-difluoropiperidin-1-yl)pyrimidine-4-carboxylic acid
[0450] 2-(4,4-difluoropiperidin-1-yl)pyrimidine-4-carboxylic acid
[0451] 2-Chloropyrimidine-4-carboxylic acid 14a (0.2 g, 1.26 mmol) and 4,4-difluoropiperidine (0.23 g, 1.89 mmol) were dissolved in dimethyl sulfoxide (5 mL), and cesium carbonate (0.82 g, 2.52 mmol) was added. The mixture was stirred at 140°C for 8 hours. LCMS confirmed the complete reaction. The reaction solution was poured into water, and the pH was adjusted to 3-4 with 1M hydrochloric acid. The mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to afford 2-(4,4-difluoropiperidin-1-yl)pyrimidine-4-carboxylic acid 14b (0.26 g) in an 84.7% yield.
[0452] MS m / z(ESI):244.1[M+H] +
[0453] Step 2
[0454] (1R,5S)-3-(5-bromo-2-nitrophenyl)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]
[0455] 2-Fluoro-4-bromonitrobenzene 14c (0.6 g, 2.73 mmol) and (1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane] 2d (0.71 g, 4.09 mmol) were dissolved in dimethyl sulfoxide (10 mL). Cesium carbonate (1.78 g, 5.45 mmol) was added, and the mixture was stirred at 140°C for 8 hours. TLC confirmed the complete reaction. Saturated brine (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: System A) to afford (1R,5S)-3-(5-bromo-2-nitrophenyl)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane] 14d (0.8 g) in 87% yield.
[0456] Step 3
[0457] N-(4-nitro-3-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)phenyl)ethanesulfonamide
[0458] N-(4-Nitro-3-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)phenyl)ethylsulfonamide
[0459] (1R,5S)-3-(5-bromo-2-nitrophenyl)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane] 14d (0.35 g, 1.04 mmol) was dissolved in N,N-dimethylformamide (8 mL), and ethylsulfonamide 7b (0.23 g, 2.08 mmol), cuprous iodide (59.3 mg, 0.31 mmol), (1R,2R)-(-)-N,N'-dimethyl-1,2-cyclohexanediamine (0.13 g, 0.93 mmol), and potassium phosphate trihydrate (0.55 g, 2.08 mmol) were added, and the mixture was stirred at 100°C under nitrogen atmosphere for 5 hours. LCMS detection showed that the reaction of the raw material was complete, and saturated brine (20 mL) was added, extracted with ethyl acetate (20 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give the product N-(4-nitro-3-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)phenyl)ethylsulfonamide 14e (0.46 g).
[0460] MS m / z(ESI):366.2[M+H] +
[0461] Step 4
[0462] N-(4-amino-3-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropan]-3-yl)phenyl)ethanesulfonamide
[0463] N-(4-Amino-3-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)phenyl)ethylsulfonamide
[0464] N-(4-nitro-3-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)phenyl)ethylsulfonamide 14e (0.46 g, 1.26 mmol) was dissolved in ethanol (10 mL) and water (2 mL). Iron powder (0.28 g, 5.03 mmol) and ammonium chloride (0.40 g, 7.55 mmol) were added and stirred at 85 °C for 3 h. LCMS indicated that the reaction was complete. After the reaction mixture was cooled to room temperature, sodium bicarbonate solution was added to adjust the pH to alkaline. The reaction mixture was filtered through a pad of celite, and the filter cake was rinsed with ethyl acetate (20 mL). The filtrate was concentrated, and the resulting residue was purified by silica gel column chromatography (eluent: System A) to obtain N-(4-amino-3-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)phenyl)ethylsulfonamide 14f (0.2 g) in a 47.4% yield. MS m / z (ESI): 336.2 [M+H]. +
[0465] Step 5
[0466] 2-(4,4-difluoropiperidin-1-yl)-N-(4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicycle[3.2.1]octane-8,1'-cyclopropan]-3-yl)phenyl)pyrimidine-4-carboxamide
[0467] 2-(4,4-difluoropiperidin-1-yl)-N-(4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)phenyl)pyridine-4-carboxamide
[0468] N-(4-Amino-3-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)phenyl)ethylsulfonamide 14f (0.2 g, 0.60 mmol) and 2-(4,4-difluoropiperidin-1-yl)pyrimidine-4-carboxylic acid 14b (0.15 g, 0.61 mmol) were dissolved in N,N-dimethylformamide (5 mL), and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 0.34 g, 0.89 mmol) and diisopropylethylamine (0.23 g, 1.79 mmol) were added, and the mixture was stirred at room temperature for 3 hours. The reaction of the starting material was complete as monitored by LCMS. Saturated brine (20 mL) was added and the mixture was extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) and then by preparative liquid chromatography (AKZONOBEL Kromasil column; 250×21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% TFA+H2O, mobile phase B: CH3CN) to give the product 2-(4,4-difluoropiperidin-1-yl)-N-(4-(ethylsulfonamido)-2-((1R,5S)-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-yl)phenyl)pyridine-4-carboxamide 14 (0.12 g) in a yield of 33.4%.
[0469] MS m / z(ESI):561.3[M+H] +
[0470] 1 H NMR(400MHz,DMSO-d6)δ9.80(s,1H),9.72(s,1H),8.70(d,J=4.8Hz,1H),7.94(d,J=8.7Hz,1H), 7.32(d,J=4.8Hz,1H),7.17(d,J=2.4Hz,1H),6.99(dd,J=8.7,2.4Hz,1H),4.02(t,J=5.8Hz,4H), 3.07(q,J=7.3Hz,2H),2.92-2.77(m,4H),2.12-2.00(m,4H),1.99-1.93(m,2H),1.87-1.78(m,2 H), 1.42 (s, 2H), 1.19 (t, J = 7.3Hz, 3H), 0.62 (dd, J = 8.7, 5.9Hz, 2H), 0.35 (dd, J = 8.7, 5.9Hz, 2H).
[0471] Example 15 and Example 16
[0472] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1S,6S)-6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0473] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1S,6S)-6-methyl-3-azabicyclo[4.1.0]heptane-3-yl)benzamide 15
[0474] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,6R)-6-methyl-3-azabicyclo[4.1.0]heptan-3-yl)benzamide
[0475] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,6R)-6-methyl-3-azabicyclo[4.1.0]heptane-3-yl)benzamide 16
[0476] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-methyl-3-azabicyclo[4.1.0]heptane-3-yl)benzamide 5 was chirally resolved (Column: Mobile Phase A: Supercritical CO2; Mobile Phase B: IPA (+0.1% DEA)) to give N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1S,6S)-6-methyl-3-azabicyclo[4.1.0]heptane-3-yl)benzamide 15 and N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-((1R,6R)-6-methyl-3-azabicyclo[4.1.0]heptane-3-yl)benzamide 16.
[0477] Compounds with shorter retention times in 15 and 16:
[0478] MS m / z(ESI):565.2[M+H] +
[0479] 1 H NMR (400MHz, DMSO-d6) δ11.66(s,1H),7.89(d,J=8.6Hz,1H),7.69(dd,J=13.1,9.7Hz,1H),7.43(s,1H),7.16(d,J=1. 6Hz,1H),7.05(dd,J=8.6,1.8Hz,1H),3.95-3.86(m,4H),3.82(s,1H),3.75(t,J=6.5Hz,2H),3.35(s,2H),3.24(dd,J= 11.3,5.1Hz,1H),3.08(d,J=11.3Hz,1H),2.70(ddd,J=21.2,12.0,5.6Hz,2H),2.31(s,3H),2.20-2.08(m,1H),2.05-1 .90(m,4H),1.79(dd,J=9.1,4.8Hz,1H),1.12(s,3H),1.00(ddd,J=20.3,9.4,5.2Hz,2H),0.47(dd,J=8.5,3.8Hz,1H).
[0480] Compounds with longer retention times in 15 and 16:
[0481] MS m / z(ESI):565.2[M+H] +
[0482] 1H NMR (400MHz, DMSO-d6) δ11.69(s,1H),7.89(d,J=8.6Hz,1H),7.71(ddd,J=9.0,5.6,3.0Hz,1H),7.43(s,1H),7 .15(d,J=1.8Hz,1H),7.04(dd,J=8.6,1.9Hz,1H),3.97–3.86(m,4H),3.82(s,1H),3.75(t,J=6.5Hz,2H),3.30( s,2H),3.24(dd,J=11.3,5.2Hz,1H),3.08(d,J=11.3Hz,1H),2.80-2.60(m,2H),2.31(s,3H),2.20-2.08(m,1H ),2.06-1.90(m,4H),1.79(dd,J=9.2,4.7Hz,1H),1.12(s,3H),1.07-0.92(m,2H),0.47(dd,J=8.5,3.9Hz,1H).
[0483] Biological evaluation
[0484] Test Example 1: Determination of the Inhibitory Effect of the Compounds of the Invention on OVCAR-3 Cell Proliferation
[0485] The following method was used to determine the effect of the compounds of the present invention on the proliferation of OVCAR-3 cells. OVCAR-3 cells (containing the TP53 R248Q mutation) were purchased from the Cell Resource Center of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and cultured in RPMI 1640 medium containing 10% fetal bovine serum, 100 U penicillin, and 100 μg / mL streptomycin. Cell viability was measured by The assay was performed using the Luminescent Cell Viability Assay Kit (Promega, Cat. No. G7573).
[0486] The experimental method was performed according to the steps in the kit instructions, which are briefly described as follows: the test compound was first dissolved in DMSO to prepare a 10mM stock solution, and then diluted with culture medium to prepare the test sample. The final concentration of the compound ranged from 1000nM to 0.015nM. Cells in the logarithmic growth phase were seeded into 96-well cell culture plates at a density of 1000 cells per well and cultured overnight in a 37°C, 5% CO2 incubator. The test compound was then added and cultured for another 72 hours. After the culture was completed, 50uL of CellTiter-Glo detection solution was added to each well, shaken for 5 minutes, and then allowed to stand for 10 minutes. The luminescence value of each sample well was then read on a microplate reader using the Luminescence mode. The percentage inhibition rate of the compound at each concentration point was calculated by comparing it with the value of the control group (0.3% DMSO). Nonlinear regression analysis was then performed in GraphPad Prism 5 software using the logarithm of the compound concentration-inhibition rate to obtain the IC value of the compound for inhibiting cell proliferation. 50 The results are shown in Table 1.
[0487] IC of the compounds of the present invention 50 The value results are represented by A, B, and C, respectively:
[0488] "A" stands for IC 50 ≤200nM; "B" means 200nM <IC 50 ≤500nM; “C” represents IC 50 >500nM.
[0489] Table 1 Inhibitory activity of the compounds of the present invention on OVCAR-3 cell proliferation
[0490] Conclusion: The compounds of the present invention have an IC inhibitory effect on the proliferation of OVCAR-3 cells. 50 <200nM, with good inhibitory effect.
[0491] Test Example 2: Determination of the Inhibitory Effect of the Compounds of the Invention on HT-29 Cell Proliferation
[0492] The following method was used to determine the effect of the compounds of the present invention on HT-29 cell proliferation. HT-29 cells (containing the TP53R273H mutation) were purchased from the Cell Resource Center of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and cultured in McCoy's 5A medium containing 10% fetal bovine serum, 100 U penicillin, and 100 μg / mL streptomycin. Cell viability was measured by The assay was performed using the Luminescent Cell Viability Assay Kit (Promega, Cat. No. G7573).
[0493] The experimental method was performed according to the steps in the kit instructions and is briefly described as follows: the test compound was first dissolved in DMSO to prepare a 10mM stock solution, and then diluted with culture medium to prepare the test sample. The final concentration of the compound ranged from 1000nM to 0.015nM. Cells in the logarithmic growth phase were seeded into 96-well cell culture plates at a density of 1000 cells per well and cultured overnight in a 37°C, 5% CO2 incubator. The test compound was then added and cultured for another 120 hours. After the incubation period, 50uL of CellTiter-Glo detection solution was added to each well, shaken for 5 minutes, and then allowed to stand for 10 minutes. The luminescence value of each sample well was then read on a microplate reader using the Luminescence mode. The percentage inhibition rate of the compound at each concentration point was calculated by comparing it with the value of the control group (0.3% DMSO). Nonlinear regression analysis was then performed in GraphPad Prism 5 software using the logarithm of the compound concentration-inhibition rate to obtain the IC value of the compound for inhibiting cell proliferation. 50 The results are shown in Table 2.
[0494] IC of the compounds of the present invention 50 The value results are represented by A, B, and C, respectively:
[0495] "A" stands for IC 50 ≤200nM; "B" means 200nM <IC 50 ≤500nM; “C” represents IC 50 >500nM.
[0496] Table 2: Inhibitory activity of the compounds of the present invention on HT-29 cell proliferation
[0497] Conclusion: The compounds of the present invention have an inhibitory effect on the proliferation of HT-29 cells. 50 <200nM, with good inhibitory effect.
[0498] Test Example 3: Test of the Inhibition of KIF18A Enzyme Activity by the Compounds of the Invention
[0499] The following method is used to determine the degree of inhibition of the compound of the present invention on the activity of recombinant human KIF18A enzyme under in vitro conditions. This method uses Promega's ADP-Glo TM Kinase Assay Kit (Cat. No. V9102). Detailed experimental procedures can be found in the kit instructions.
[0500] The experimental process is briefly described as follows: the test compound is first dissolved in DMSO to prepare a stock solution, and then gradiently diluted using reaction buffer A (15mM Tris, pH 7.5, 10mM MgCl2, 0.01% Pluronic F-68). The final concentration of the test compound in the reaction system ranges from 10000nM to 0.15nM; KIF18A protein and ATP working solution are prepared using reaction buffer B (15mM Tris, pH 7.5, 10mM MgCl2, 0.01% Pluronic F-68, 37.5ug / ml tubulin, 1.25uM paclitaxel). The reaction is carried out in a 384-well microplate. First, the compound and recombinant human KIF18A protein (final concentration 100nM, expressed by GenScript) are added to the wells and incubated at room temperature for 20 minutes. Then, ATP solution (from ADP-Glo) is added to the reaction solution. TM Kinase Assay kit component V915A, final concentration 60uM) and incubate at room temperature for 20 minutes. Subsequently, 5μL ADP-Glo Reagent was added to the reaction system and incubated at room temperature for 50 minutes. Thereafter, 10μL Kinase Detection Reagent was added to the reaction system and incubated at room temperature for 30 minutes. After the incubation, the chemiluminescence intensity value of each well was measured in the luminescence mode on the microplate reader. The percentage inhibition rate of the compound at each concentration was calculated by comparing the luminescence intensity ratio with the control group (0.1% DMSO), and the nonlinear regression analysis of the compound concentration-inhibition rate was performed using GraphPad Prism 5 software to obtain the IC value of the compound. 50 Values are shown in Table 3.
[0501] IC of the compounds of the present invention 50 The value results are represented by A, B, and C, respectively:
[0502] "A" stands for IC 50 ≤200nM; "B" means 200nM <IC 50 ≤500nM; “C” represents IC 50 >500nM.
[0503] Table 3 IC values of the compounds of the present invention for inhibiting KIF18A enzyme activity 50 data
[0504] Conclusion: The compounds of the present invention have an inhibitory effect on KIF18A enzyme activity. 50 <500nM, with significant inhibitory effect.
Claims
1. A compound represented by general formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof: in: G is selected from a 5- to 10-membered bridged heterocyclic group, a 5- to 10-membered fused heterocyclic group or a 7- to 14-membered bispiro heterocyclic group, wherein the bridged heterocyclic group or fused heterocyclic group is optionally further substituted by one or more R A replaced by; R A is selected from halogen, hydroxy, cyano, alkyl, cycloalkyl or alkoxy, wherein the alkyl, cycloalkyl or alkoxy is optionally further substituted with one or more substituents selected from halogen, hydroxy, cyano, alkyl or alkoxy; Or, two R A The same carbon atom to which it is connected forms a -C(O), -C=CR g R h , 3-6 membered cycloalkyl or 3-6 membered heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally further substituted by one or more substituents selected from halogen, hydroxyl, cyano, alkyl, haloalkyl, alkoxy or =O; R g , R h are each independently selected from a hydrogen atom, a deuterium atom, a halogen or an alkyl group; X1 and X2 are each independently selected from CR a or N atoms; Y1, Y2, and Y3 are each independently selected from CR b or N atoms, and at most two atoms among Y1, Y2, and Y3 are N atoms at the same time; R a , R b Each is independently selected from a hydrogen atom, a halogen, a hydroxyl, a cyano group, an alkyl group, an alkoxy group, -C(O)NH2, -N(CH3)2 or an acetyl group; wherein the alkyl group or the alkoxy group is optionally further substituted with one or more substituents selected from a halogen, a hydroxyl, a cyano group, an alkyl group, -N(CH3)2 or an alkoxy group; L1 is selected from a bond, -C 1-6 Alkylene-, -C 0-4 Alkylene-NR c S(=O)(=NH)-C 0-4 Alkylene-, -C 0-4 Alkylene-SC 0-4 Alkylene-, -C 0-4 Alkylene-S(=O)-C 0-4 Alkylene-, -C 0-4 Alkylene-SO2-C 0-4 Alkylene-, -C 0-4 Alkylene-S(=O)(=NH)-C 0-4 Alkylene-, -C 0-4 Alkylene-NR c SO2-C 0-4 Alkylene-, -C 0-4 Alkylene-SO2NR c -C 0-4 Alkylene-, -C 0-4 Alkylene-OC 0-4 Alkylene-, -C 0-4 Alkylene-NR c -C 0-4 Alkylene-, -C 0-4 Alkylene-NR c SO2NR c -C 0-4 Alkylene-, -C 0-4 Alkylene-NR c C(O)NR c -C 0-4 Alkylene-, -C 0-4 Alkylene-C(O)NR c -C 0-4 Alkylene-, -C 0-4 Alkylene-NR c C(O)-C 0-4 Alkylene-, -C 0-4 Alkylene-PC 0-4 Alkylene-, -C 0-4 Alkylene-P(=O)2-C 0-4 Alkylene, -C 0-4 Alkylene-C(=O)-C 0-4 Alkylene- or -C 0-4 Alkylene-C(=N(OH))-C 0-4 Alkylene-, wherein the -C 1-6 Alkylene- or -C 0-4 Alkylene - optionally further substituted with one or more substituents selected from halogen, hydroxy, cyano, cycloalkyl or alkoxy; R c are each independently selected from a hydrogen atom, an alkyl group or a cycloalkyl group; R 1 is selected from hydrogen, cyano, halogen, alkyl, hydroxy, cycloalkyl, heterocyclic, aryl or heteroaryl; wherein the alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted with one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic, Aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent; L2 is selected from R B Each is independently selected from a hydrogen atom, an alkyl group or a cycloalkyl group, wherein the alkyl group or the cycloalkyl group is optionally further substituted by one or more substituents selected from halogen, hydroxyl, cyano or alkoxy. Preferably, R B is a hydrogen atom; R 2 , R 3 Each is independently selected from a hydrogen atom, a halogen, a hydroxyl, a cyano group, an alkyl group, a cycloalkyl group or an alkoxy group; wherein the alkyl group, the cycloalkyl group or the alkoxy group is optionally further substituted by one or more substituents selected from a halogen, a hydroxyl, a cyano group, an alkyl group or an alkoxy group; Or, R 2 and R 3 Together with the carbon atom to which it is attached, it forms a 5-7 membered cycloalkyl, 5-7 membered heteroaryl or 5-7 membered heterocyclic group, wherein the cycloalkyl, heteroaryl or heterocyclic group is optionally further substituted by one or more substituents selected from halogen, hydroxyl, cyano, alkyl, haloalkyl, cycloalkyl, alkoxy, haloalkoxy or =O; R 4 is selected from cyano, halogen, alkyl, hydroxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR 5 、-C(O)R 5 、-C(O)OR 5 、-NHC(O)R 5 、-NHC(O)OR 5 、-NR 6 R 7 、-C(O)NR 6 R 7 、-CH2NHC(O)OR 5 、-CH2NR 6 R 7 or -S(O) r R 5 wherein the alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent; Or, when X2 is CR a When R 3 or R 4 and R a The carbon atom to which it is connected forms a 5-7 membered cycloalkyl, 5-7 membered heteroaryl or 5-7 membered heterocyclic group, wherein the cycloalkyl, heteroaryl or heterocyclic group is optionally further substituted with one or more selected from halogen, hydroxyl, cyano, alkyl, cycloalkyl, alkoxy, haloalkoxy, -OR 11 or substituted by a substituent of =O; Or, when X1 is CR a When R 4 and R a The carbon atom to which it is connected forms a 5-7 membered cycloalkyl, 5-7 membered heteroaryl or 5-7 membered heterocyclic group, wherein the cycloalkyl, heteroaryl or heterocyclic group is optionally further substituted with one or more selected from halogen, hydroxyl, cyano, alkyl, cycloalkyl, alkoxy, haloalkoxy, -OR 11 or substituted by a substituent of =O; R 11 Each is independently selected from cycloalkyl or heterocyclic group; wherein the cycloalkyl or heterocyclic group is optionally further substituted by one or more substituents selected from hydroxyl, halogen, cyano, alkyl, alkoxy, haloalkyl; R 5 Each is independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted by one or more selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic group, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent; R 6 and R 7 Each is independently selected from hydrogen, hydroxy, halogen, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent; Or, R 6 and R 7 Together with the atoms to which they are attached, they form a 4- to 8-membered heterocyclic group, wherein the 4- to 8-membered heterocyclic group contains one or more N, O or S(O)r, and the 4- to 8-membered heterocyclic group is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic group, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent; R 8 , R 9 and R 10 Each is independently selected from a hydrogen atom, an alkyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted by one or more substituents selected from a hydroxyl group, a halogen group, a nitro group, an amino group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, a carboxyl group or a carboxylate group; r is independently 0, 1 or 2.
2. The compound according to claim 1 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is a compound or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof according to general formula (II-1) or (II-2): in, G, X1, X2, Y1, Y2, Y3, R 1 ~R 4 and L1 are as defined in claim 1.
3. The compound according to claim 1 or 2, or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein G is selected from the following groups: in, R A Each is independently selected from halogen, hydroxy, cyano, methyl, trifluoromethyl, cyclopropyl or methoxy; Or, two R A to the same carbon atom to which it is attached, forming a cyclopropyl or cyclobutyl group; n is each independently selected from 0, 1, 2 or 3.
4. The compound according to claim 3 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein G is selected from the following groups:
5. The compound according to claim 1 or 2, or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein: L1 is selected from a bond, -NR c -C 0-4 Alkylene-, -NR c SO2-C 0-4 Alkylene-, -SO2NR c -C 0-4 Alkylene-, -NR c SO2NR c -, -S(=O)(=NH)-, -NR c S(=O)(=NH)-、-C 1-4 Alkylene-, -S(=O)-, -O-, -C(=O)-, -C(=O)NR c -C 0-4 Alkylene-, -C 0-4 Alkylene-SO2-C 0-4 Alkylene-, -C=N(OH)- or -NR c -C(=O)-, wherein the -C 0-4 Alkylene- or -C 1-4 Alkylene - optionally further substituted with one or more substituents selected from halogen, hydroxy, cyano, cyclopropyl or methoxy; R c Each is independently selected from a hydrogen atom or a methyl group.
6. The compound according to claim 1 or 2, or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein: L1 is selected from a bond, -NHCH2CH2-, -NHSO2-, -NHSO2CH2-, -NHSO2CH2CH2-, -SO2NH-, -SO2NHCH2CH2-, -NHSO2NH-, -NHSO2N(CH3)-, -SO2-, -CH2SO2-, -S(=O)(=NH)-, -NHC(CH3)2CH2-, -C(O)NHCH2CH2-, -C(O)NHC(CH3)2CH2-, -C(O)N(CH3)CH2CH2-, -NHSO2CH(CH3)CH2-, -SO2NHC(CH3)2CH2-, -C(O)NH- or -CH2SO2CH2CH2-.
7. The compound according to claim 1 or 2, or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R 1 is selected from a hydrogen atom, a hydroxyl group, an alkyl group, a heterocyclic group, a cycloalkyl group or a heteroaryl group, wherein the alkyl group, the heterocyclic group, the cycloalkyl group or the heteroaryl group is optionally further substituted by one or more substituents selected from a hydroxyl group or an alkyl group.
8. The compound according to claim 1 or 2, or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein for 9. The compound according to claim 1 or 2, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, wherein X1 and X2 are each independently selected from CH or N.
10. The compound according to claim 1 or 2, or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R 2 , R 3 Each is independently selected from a hydrogen atom or an alkyl group; preferably, the alkyl group is a methyl group.
11. The compound according to claim 1 or 2, or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R 4 Each is independently selected from a 3- to 10-membered heterocyclyl or a 3- to 10-membered cycloalkyl, wherein the heterocyclyl or cycloalkyl is optionally further substituted by one or more alkyl or halogen.
12. The compound according to claim 11 or its stereoisomer, tautomer or pharmaceutically acceptable salt, wherein R 4 for 13. The compound according to any one of claims 1 to 12, or its stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein the compound is:
14. A pharmaceutical composition comprising an effective dose of the compound according to any one of claims 1 to 13 or its stereoisomer, tautomer or pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, excipient or a combination thereof.
15. Use of the compound according to any one of claims 1 to 13 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 14 in the preparation of a KIF18A inhibitor.
16. Use of the compound according to any one of claims 1 to 13 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 14 in the preparation of a medicament for treating a disease mediated by KIF18A; preferably, the disease mediated by KIF18A is cancer.
17. The use according to claim 16, wherein the cancer is selected from hepatocellular carcinoma, glioblastoma, colon cancer, breast cancer, lung cancer, bile duct cancer, pancreatic cancer, prostate cancer, bladder cancer, head cancer, neck cancer, cervical cancer, ovarian cancer, synovial sarcoma, rhabdomyosarcoma, colorectal cancer or lung adenocarcinoma.
18. Use of the compound according to any one of claims 1 to 13 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 14 in the preparation of a drug for treating cancer.
19. The method of claim 18, wherein the cancer is selected from hepatocellular carcinoma, glioblastoma, colon cancer, breast cancer, lung cancer, bile duct cancer, pancreatic cancer, prostate cancer, bladder cancer, head cancer, neck cancer, cervical cancer, ovarian cancer, synovial sarcoma, rhabdomyosarcoma, colorectal cancer or lung adenocarcinoma.
Citation Information
Patent Citations
2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
CN113272293A
Inhibitor of kinin KIF18A and application thereof
CN116789637A
KIF18A inhibitor compound, pharmaceutical composition as well as preparation method and application of KIF18A inhibitor compound and pharmaceutical composition
CN117510463A
Arylamide compound and composition and application thereof
CN117683017A
2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors
WO2020092187A1
Cited By
Inhibitors of KIF18A and uses thereof
US12391709B2
